Published in final edited form as:

Int Rev Neurobiol. 2009 ; 88: 257–296. doi:10.1016/S0074-7742(09)88010-0.

NEURAL AND CARDIAC TOXICITIES ASSOCIATED WITH 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA)

Michael H. Baumann and Richard B. Rothman

Clinical Psychopharmacology Section, Intramural Research Program (IRP), National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), Baltimore, Maryland 21224, USA

Abstract

(±)-3,4-Methylenedioxymethamphetamine (MDMA) is a commonly abused illicit drug which affects multiple organ systems. In animals, high-dose administration of MDMA produces deficits in serotonin (5-HT) neurons (e.g., depletion of forebrain 5-HT) that have been viewed as neurotoxicity. Recent data implicate MDMA in the development of valvular heart disease (VHD). The present paper reviews several issues related to MDMA-associated neural and cardiac toxicities. The hypothesis of MDMA neurotoxicity in rats is evaluated in terms of the effects of MDMA on monoamine neurons, the use of scaling methods to extrapolate MDMA doses across species, and functional consequences of MDMA exposure. A potential treatment regimen (L-5-hydroxytryptophan plus carbidopa) for MDMA-associated neural deficits is discussed. The pathogenesis of MDMA-associated VHD is reviewed with specific reference to the role of valvular 5-HT_{2B} receptors. We conclude that pharmacological effects of MDMA occur at the same doses in rats and humans. High doses of MDMA that produce 5-HT depletions in rats are associated with tolerance and impaired 5-HT release. Doses of MDMA that fail to deplete 5-HT in rats can cause persistent behavioral dysfunction, suggesting even moderate doses may pose risks. Finally, the MDMA metabolite, 3,4-methylenedioxyamphetamine (MDA), is a potent 5-HT_{2B} agonist which could contribute to the increased risk of VHD observed in heavy MDMA users.

I. Introduction

3,4-Methylenedioxymethamphetamine (MDMA or *Ecstasy*) is a popular illicit drug in the United States, Europe, and elsewhere. The allure of MDMA is likely related to its unique profile of psychotropic effects which includes amphetamine-like mood elevation, coupled with feelings of increased emotional sensitivity and closeness to others (Liechti and Vollenweider, 2001; Vollenweider *et al.*, 1998). MDMA misuse among adolescents is widespread in the United States (Landry, 2002; Yacoubian, 2003), and a recent sampling of high school seniors found 10% reported using MDMA at least once (Banken, 2004). The incidence of MDMA-related medical complications has risen in parallel with the increasing popularity of the drug. Serious adverse effects of MDMA intoxication include hyperthermia, serotonin (5-HT) syndrome, cardiac arrhythmias, hypertension, hyponatremia, liver problems, seizures, coma, and death (Schifano, 2004). Accumulating evidence suggests that heavy MDMA use is associated with cognitive impairments, mood disturbances, and cardiac valve dysfunction, in some cases lasting for months after cessation of drug intake (Morgan, 2000; Parrott, 2002). Despite the risks of illicit MDMA use, a number of clinicians believe the drug has therapeutic value in the treatment of psychiatric disorders, such as posttraumatic stress disorder (Doblin, 2002), and clinical studies with MDMA are underway (see <http://clinicaltrials.gov>). In controlled research settings, MDMA has been administered safely to humans, but adverse effects have been documented in certain individuals (Harris *et al.*, 2002; Mas *et al.*, 1999).

These considerations provide compelling reasons to evaluate the pharmacology and toxicology of MDMA. The present paper several issues related to MDMA-associated toxicities. The hypothesis of MDMA neurotoxicity in rats is evaluated in terms of MDMA effects on monoamine neurons, the use of scaling methods to adjust MDMA doses across species, and functional consequences of MDMA-induced 5-HT depletions. A potential treatment regimen (L-5-hydroxytryptophan plus carbidopa) for MDMA-associated neural deficits is discussed. The pathogenesis of MDMA-associated valvular heart disease (VHD) is reviewed with particular reference to the role of 5-HT_{2B} receptors. Previously published data from our laboratory at the National Institute on Drug Abuse (NIDA) will be included to supplement literature reports. Clinical findings will be mentioned in specific instances to note comparisons between rats and humans.

The neurotoxicity aspect of this review will focus on data obtained from rats since most preclinical MDMA research has been carried out in this animal model. Data from mice will not be considered because this species displays the unusual characteristic of long-term dopamine (DA) depletions (i.e., DA neurotoxicity) in response to MDMA, rather than long-term 5-HT depletions observed in rats, nonhuman primates, and most other animals (reviewed by Colado *et al.*, 2004). We will not address possible molecular mechanisms underlying MDMA-induced 5-HT deficits, as several excellent reviews have covered this subject (Lyles and Cadet, 2003; Monks *et al.*, 2004; Sprague *et al.*, 1998). All experiments in our laboratory utilized male Sprague–Dawley rats (Wilmington, MA) weighing 300–350 g. Rats were maintained in facilities accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care, and procedures were carried out in accordance with the Animal Care and Use Committee of the NIDA Intramural Research Program (IRP).

II. Effects of MDMA on Monoamine Neurons

In order to critically evaluate the hypothesis of MDMA-induced 5-HT neurotoxicity, a brief review of MDMA pharmacology is necessary. Figure 1 shows that MDMA is a ring-substituted analog of methamphetamine. *Ecstasy* tablets ingested by humans contain a racemic mixture of (+) and (–) isomers of MDMA, and both isomers are bioactive (Johnson *et al.*, 1986; Schmidt, 1987). *Ecstasy* tablets often contain other psychoactive substances such as substituted amphetamines, caffeine, or ketamine, which can contribute to the overall effects of the ingested preparation (Parrott, 2004). Upon systemic administration, *N*-demethylation of MDMA occurs via first-pass metabolism to yield the ring-substituted amphetamine analog 3,4-methylenedioxyamphetamine (MDA) (de la Torre *et al.*, 2004). Initial studies carried out in the 1980s showed that MDMA and MDA stimulate efflux of preloaded [³H]5-HT, and to a lesser extent [³H]DA, in nervous tissue (Johnson *et al.*, 1986; Nichols *et al.*, 1982; Schmidt *et al.*, 1987). Subsequent findings revealed that MDMA interacts with monoamine transporter proteins to stimulate nonexocytotic release of 5-HT, DA, and norepinephrine (NE) in rat brain (Berger *et al.*, 1992; Crespi, 1997; Fitzgerald and Reid, 1993).

Like other substrate-type releasers, MDMA and MDA bind to transporter proteins and are subsequently transported into the cytoplasm of nerve terminals, releasing neurotransmitters via a process originally described as carrier-mediated exchange (for review see Rothman and Baumann, 2006; Rudnick and Clark, 1993). However, the mechanism by which substrates induce the release of neurotransmitters is more complicated than a simple exchange process. Recent studies of the DA transporter (DAT) have shown that inward transport of a substrate like amphetamine is accompanied by an inward sodium current, which increases the concentration of intracellular sodium at the transporter, thereby facilitating reverse transport of DA (Goodwin *et al.*, 2008; Piffl *et al.*, 2009). Determining the

precise molecular mechanism of transporter-mediated release of 5-HT is a topic of ongoing research.

Table I summarizes published data from our laboratory showing structure–activity relationships for stereoisomers of MDMA, MDA, and related drugs as monoamine releasers in rat brain synaptosomes (Partilla *et al.*, 2000; Rothman *et al.*, 2001; Setola *et al.*, 2003). Stereoisomers of MDMA and MDA are substrates for 5-HT transporters (SERT), NE transporters (NET), and DAT, with (+) isomers exhibiting greater potency as releasers. In particular, (+) isomers of MDMA and MDA are much more effective DA releasers than their corresponding (–) isomers. It is noteworthy that (+) isomers of MDMA and MDA are rather nonselective in their ability to stimulate monoamine release *in vitro*. When compared to amphetamine and methamphetamine, the major effect of methylenedioxy ring-substitution is enhanced potency for 5-HT release and reduced potency for DA release. For example, (+)-MDMA releases 5-HT ($EC_{50} = 70.8$ nM) about 10 times more potently than (+)-methamphetamine ($EC_{50} = 736$ nM), whereas (+)-MDMA releases DA ($EC_{50} = 142$ nM) about six times less potently than (+)-methamphetamine ($EC_{50} = 24$ nM).

Consistent with *in vitro* results, *in vivo* microdialysis experiments demonstrate that MDMA increases extracellular 5-HT and DA in rat brain, with effects on 5-HT being greater in magnitude (Baumann *et al.*, 2005; Gudelsky and Nash, 1996; Kankaanpää *et al.*, 1998; Yamamoto *et al.*, 1995). Figure 2 depicts data from our laboratory showing the stimulatory effects of MDMA on extracellular 5-HT and DA in rat n. accumbens (Baumann *et al.*, 2005). In these experiments, rats undergoing microdialysis received i.v. injections of 1 mg/kg MDMA at time zero, followed by 3 mg/kg MDMA 60 min later. Importantly, these doses of MDMA are comparable to those used in rat self-administration paradigms (Ratzenboeck *et al.*, 2001; Schenk *et al.*, 2003). In all of our microdialysis studies, samples are collected at 20 min intervals beginning 1 h before injections, until 1 h after the second dose of drug; samples are assayed for 5-HT and DA by high-performance liquid chromatography coupled to electrochemical detection (HPLC-ECD) (Baumann and Rutter, 2003). Neurochemical data are expressed as pg/5 μ l sample. MDMA causes significant dose-related increases in dialysate 5-HT [$F_{8,45} = 33.04$, $P < 0.0001$] and DA [$F_{8,45} = 5.56$, $P < 0.001$] in n. accumbens. At both doses, elevations in extracellular 5-HT are much greater than corresponding elevations in DA. For example, the 1 mg/kg dose of MDMA produces a 7.5-fold rise in 5-HT but only a 1.5-fold rise in DA.

Acute central nervous system (CNS) effects of MDMA are presumably mediated by release of monoamine transmitters, with the subsequent activation of pre- and postsynaptic receptors (reviewed by Cole and Sumnall, 2003; Green *et al.*, 2003). As a specific example in rats, MDMA elicits a unique spectrum of motor actions characterized by forward locomotion (i.e., ambulation) and elements of the 5-HT behavioral syndrome such as forepaw treading and head weaving (i.e., stereotypy) (Gold *et al.*, 1988; Slikker *et al.*, 1989; Spanos and Yamamoto, 1989). It is well established that hyperactivity caused by MDMA is dependent upon activation of multiple 5-HT and DA receptor subtypes in the brain (reviewed by Bankson and Cunningham, 2001; Geyer, 1996). We examined the role of brain monoamines in mediating locomotor effects of MDMA by combining *in vivo* microdialysis with automated analysis of motor behaviors (Baumann *et al.*, 2008b). Microdialysis guide cannulae were aimed at various brain regions implicated in motor stimulation, including n. accumbens, striatum, and prefrontal cortex. Conscious rats undergoing microdialysis were housed in chambers equipped with photobeams to assess ambulation and stereotypy. Neurochemical and locomotor effects of MDMA administration were determined simultaneously in the same individual rats, thereby allowing the use of Pearson correlation analysis to examine relationships between pg amounts of transmitter, distance traveled and stereotypic events. Figure 3 depicts representative data from the n. accumbens where

MDMA-induced elevations in dialysate 5-HT are positively correlated with stereotypy [$r = 0.5276$, $P < 0.0001$] but not ambulation [$r = 0.3241$, NS]. On the other hand, Fig. 4 shows that increases in accumbens DA are highly correlated with ambulation [$r = 0.6409$, $P < 0.0001$] and somewhat less so with stereotypy [$r = 0.4490$, $P < 0.01$]. Our correlation data from various brain regions indicate that motor effects produced by MDMA involve transporter-mediated release of 5-HT and DA in a region- and modality-specific manner. Additionally, the role of NE in modulating behavioral effects of MDMA is largely unexplored, and this issue warrants further study (Selken and Nichols, 2007; Starr *et al.*, 2008).

Adverse effects of acute MDMA administration, including cardiovascular stimulation and elevated body temperature, are thought to involve monoamine release from sympathetic nerves in the periphery or nerve terminals in the CNS. MDMA increases heart rate and mean arterial pressure in conscious rats (O'Cain *et al.*, 2000); this cardiovascular stimulation is likely mediated by MDMA-induced release of peripheral NE stores, similar to the effects of amphetamine (Fitzgerald and Reid, 1994). MDMA has weak agonist actions at α_2 -adrenoreceptors and 5-HT₂ receptors that might influence its cardiac and pressor effects (Battaglia and De Souza, 1989; Lavelle *et al.*, 1999; Lyon *et al.*, 1986). Moreover, as will be described in more detail in a subsequent part of this review, MDA is a potent 5-HT_{2B} agonist and this property could contribute to adverse cardiovascular effects (Setola *et al.*, 2003). The ability of MDMA to elevate body temperature is well characterized in rats (Dafters, 1995; Dafters and Lynch, 1998; Nash *et al.*, 1988), and this response has been considered a 5-HT-mediated process. However, the data of Mechan *et al.* (2002) provide convincing evidence that MDMA-induced hyperthermia involves the activation of postsynaptic D1 receptors by released DA.

III. Long-Term Effects of MDMA on 5-HT Systems

The long-term adverse effects of MDMA on 5-HT systems have attracted substantial interest, since studies in rats and nonhuman primates show that high-dose MDMA administration produces persistent reductions in markers of 5-HT nerve terminal integrity (reviewed by Lyles and Cadet, 2003; Sprague *et al.*, 1998). Table II summarizes the findings of investigators who first demonstrated that MDMA causes long-term (>1 week) inactivation of tryptophan hydroxylase activity, depletions of brain tissue 5-HT, and reductions in SERT binding and function (Battaglia *et al.*, 1987; Commins *et al.*, 1987; Schmidt, 1987; Stone *et al.*, 1987). These serotonergic deficits are observed in various regions of rat forebrain, including frontal cortex, striatum, hippocampus, and hypothalamus. Immunohistochemical analysis of 5-HT in cortical and subcortical areas reveals an apparent loss of 5-HT axons and terminals in MDMA-treated rats, especially the fine-diameter projections arising from the dorsal raphe nucleus (O'Hearn *et al.*, 1988). Moreover, 5-HT axons and terminals remaining after MDMA treatment appear swollen and fragmented, suggesting structural damage.

Time-course studies indicate that MDMA-induced 5-HT depletions occur in a biphasic manner, with a rapid acute phase followed by a delayed long-term phase (Schmidt, 1987; Stone *et al.*, 1987). In the acute phase, which lasts for the first few h after drug administration, massive depletion of brain tissue 5-HT is accompanied by inactivation of tryptophan hydroxylase. By 24 h later, tissue 5-HT recovers to normal levels but hydroxylase activity remains diminished. In the long-term phase, which begins within 1 week and lasts for months, marked depletion of 5-HT is accompanied by sustained inactivation of tryptophan hydroxylase and loss of SERT binding and function (Battaglia *et al.*, 1988; Scanzello *et al.*, 1993). The findings summarized in Table II have been replicated by many investigators, and the spectrum of decrements is typically described as 5-HT

neurotoxicity (Baumann *et al.*, 2007; Ricaurte *et al.*, 2000). Most of the studies designed to examine MDMA neurotoxicity in rats have employed i.p. or s.c. injections of 10 mg/kg or higher, either as single or repeated treatments. These MDMA dosing regimens are known to produce significant hyperthermia, which can exacerbate 5-HT depletions caused by the drug (Green *et al.*, 2004; Malberg and Seiden, 1998). Most investigations have involved non-contingent administration of MDMA rather than self-administration, and this factor could significantly influence effects of the drug.

There are caveats to the hypothesis that MDMA produces 5-HT neurotoxicity. O'Hearn *et al.* (1988) showed that high-dose MDMA administration has no effect on 5-HT cell bodies in the dorsal raphe, despite profound loss of 5-HT in forebrain projection areas. Thus, the effects of MDMA on 5-HT neurons are sometimes referred to as "axotomy," to account for the fact that perikarya are not damaged (Molliver *et al.*, 1990; O'Hearn *et al.*, 1988). MDMA-induced reductions in 5-HT levels and SERT binding eventually recover (Battaglia *et al.*, 1988; Scanzello *et al.*, 1993), suggesting that 5-HT terminals are not destroyed. Many drugs used clinically produce effects that are similar to those produced by MDMA. For instance, reserpine causes sustained depletions of brain tissue 5-HT, yet reserpine is not considered a neurotoxin (Carlsson, 1976). Chronic administration of 5-HT selective reuptake inhibitors (SSRIs), like paroxetine and sertraline, leads to a marked loss of SERT binding and function comparable to MDMA, but these agents are therapeutic drugs rather than neurotoxins (Benmansour *et al.*, 1999; Frazer and Benmansour, 2002). Finally, high-dose administration of SSRIs produces swollen, fragmented, and abnormal 5-HT terminals which are indistinguishable from the effects of MDMA and other substituted amphetamines (Kalia *et al.*, 2000).

The caveats mentioned above raise a number of questions with respect to MDMA neurotoxicity. Of course, the most important question is whether MDMA abuse causes neurotoxic damage in humans. This complex issue is a matter of ongoing debate which has been addressed by a number of recent papers (Gouzoulis-Mayfrank *et al.*, 2002; Kish, 2002; Reneman, 2003). Clinical studies designed to critically evaluate the long-term effects of MDMA are hampered by a number of factors including comorbid psychopathology and poly-drug abuse among MDMA users. Animal models afford the unique opportunity to evaluate the effects of MDMA without many of these complicating factors, and the main focus here will be to review the evidence pertaining to MDMA-induced 5-HT neurotoxicity in rats.

IV. Scaling Methods and MDMA Dosing

A major point of controversy relates to the relevance of MDMA doses administered to rats when compared to doses taken by humans (see Cole and Sumnall, 2003). As noted earlier, MDMA regimens that produce 5-HT depletions in rats involve administration of single or multiple injections of 10–20 mg/kg, whereas the typical dose of *Ecstasy* abused by humans is one or two tablets of 80–100 mg MDMA, or 1–3 mg/kg administered orally (Green *et al.*, 2003; Schifano, 2004). Based on principles of allometric scaling (i.e., interspecies scaling), some investigators have proposed that neurotoxic doses of MDMA in rats correspond to recreational doses in humans (Ricaurte *et al.*, 2000). In order to critically evaluate this claim, a brief discussion of interspecies scaling is warranted. The concept of interspecies scaling is based upon shared biochemical mechanisms among eukaryotic cells (e.g., aerobic respiration), and was initially developed to describe variations in basal metabolic rate (BMR) between animal species of different sizes (reviewed by White and Seymour, 2005). In the 1930s, Kleiber (1932) derived what is now called the "allometric equation" to describe the relationship between body mass and BMR. The generic form of the allometric equation is: $T = aW^b$, where "T" is the variable of interest, "W" is body weight, "a" is the

allometric coefficient, and “ b ” is the allometric exponent. In the case where “ T ” is BMR, b is accepted to be 0.75. West *et al.* (2002) have shown that most biological phenomena scale according to a universal quarter-power law, as illustrated by the space-filling fractal networks of branching tubes used by the circulatory system.

Given that the allometric equation is grounded in fundamental commonalities across organisms, it is not surprising this equation can describe the relationship between body mass and physiological variables, such as BMR, heart rate, and circulation time (e.g., Noujaim *et al.*, 2004). Because circulation time and organ blood flow strongly influence drug pharmacokinetics, the allometric equation has been used in the medication development process to “scale-up” dosages from animal models to man (reviewed by Mahmood, 1999). In general, smaller animals have faster heart rates and circulation times, leading to faster clearance of exogenous drugs. This relationship does not hold true for all classes of drugs, however, especially those that are subject to complex metabolism (Lin, 1998).

MDMA is extensively metabolized in humans, as depicted in Fig. 5, and the major pathway of biotransformation involves: (1) *O*-demethylation catalyzed by cytochrome P450 2D6 (CYP2D6) and (2) *O*-methylation catalyzed by catechol-*O*-methyltransferase (COMT) (reviewed by de la Torre *et al.*, 2004). CYP2D6 and COMT are both polymorphic in humans, and differential expression of CYP2D6 isoforms leads to interindividual variations in the metabolism of 5-HT medications (e.g., SSRIs) (Charlier *et al.*, 2003). Interestingly, CYP2D6 is not present in rats, which express a homologous but functionally distinct cytochrome P450 2D1 (Malpass *et al.*, 1999; Maurer *et al.*, 2000). A minor pathway of MDMA biotransformation in humans involves *N*-demethylation of MDMA to form MDA, which is subsequently *O*-demethylated and *O*-methylated. *N*-Demethylation of MDMA represents a more important pathway for rats when compared to humans (de la Torre *et al.*, 2004). The metabolism of MDMA and MDA generates a number of metabolites, some of which may be bioactive (e.g., Escobedo *et al.*, 2005; Forsling *et al.*, 2002). Determining the potential neurotoxic properties of the various metabolites of MDMA is an important area of research (reviewed by Baumgarten and Lachenmayer, 2004; Monks *et al.*, 2004).

To complicate matters further, de la Torre *et al.* (2000) have shown that MDMA displays nonlinear kinetics in humans such that administration of increasing doses, or multiple doses, leads to unexpectedly high plasma levels of the drug. Enhanced plasma and tissue levels of MDMA are most likely related to autoinhibition of MDMA metabolism, mediated via formation of a metabolite–enzyme complex that irreversibly inactivates CYP2D6 (Wu *et al.*, 1997). Because MDMA displays nonlinear kinetics, repeated drug dosing could produce serious adverse consequences due to unusually high blood and tissue levels of the drug (Parrott, 2002; Schifano, 2004). The existing database of MDMA pharmacokinetic studies represents a curious situation where clinical findings are well documented, while preclinical data are lacking. Specifically, only a handful of animal studies have assessed the relationship between pharmacodynamic effects of MDMA and pharmacokinetics of the drug after administration of single or repeated doses (Chu *et al.*, 1996; Mechan *et al.*, 2006). Few studies have systemically characterized the nonlinear kinetics of MDMA in animal models (Mueller *et al.*, 2008). Collectively, the available data demonstrate that potential species differences in tissue drug uptake, variations in metabolic enzymes and their activities, and the phenomenon of nonlinear kinetics, preclude the use of allometric scaling to extrapolate MDMA doses across different species.

The uncertainties and limitations of allometric scaling led us to investigate the method of “effect scaling” as an alternative strategy for matching equivalent doses of MDMA in rats and humans (see Winneke and Lilienthal, 1992). In this approach, the lowest dose of drug that produces a specific pharmacological response is determined for rats and humans, and

subsequent dosing regimens in rats are calculated with reference to the predetermined threshold dose. In the case of MDMA, this strategy is simplified because CNS drug effects, such as neuroendocrine and behavioral changes, have already been investigated in different species. Theoretically, equivalent drug effects *in vivo* should reflect similar drug concentrations reaching active sites in tissue, suggesting the method of effect scaling can account for differences in drug absorption, distribution and metabolism across species (at least for low drug doses). Table III shows the doses of MDMA that produce comparable CNS effects in rats and humans. Remarkably, the findings reveal that MDMA doses in the range of 1–2 mg/kg produce pharmacological effects that are equivalent in both species. It is noteworthy that MDMA is typically administered to rats via the i.p. or s.c. route whereas humans take the drug orally. Given the similar effects of MDMA in rats and humans at the same doses, it appears that drug bioavailability is comparable after i.p., s.c., or oral administration (e.g., Finnegan *et al.*, 1988), but verification of this hypothesis awaits further investigation.

Administration of MDMA at i.p. doses of 1–3 mg/kg causes marked elevations in extracellular 5-HT and DA in rat brain, as determined by *in vivo* micro-dialysis (Baumann *et al.*, 2005; Gudelsky and Nash, 1996; Kankaanpää *et al.*, 1998). Recall the data from Fig. 2 which demonstrate that 1 mg/kg i.v. MDMA increases extracellular 5-HT and DA in rat nucleus accumbens. Although it is impossible to directly measure 5-HT and DA release in living human brain, clinical studies indicate that subjective effects of recreational doses of MDMA (1.5 mg/kg, p.o.) are mediated via transporter-mediated release of 5-HT (Liechti and Vollenweider, 2001; Liechti *et al.*, 2000). Nash *et al.* (1988) showed that i.p. injections of 1–3 mg/kg of MDMA stimulate prolactin and corticosterone secretion in rats, and similar oral doses increase plasma prolactin and cortisol in human drug users (Harris *et al.*, 2002; Mas *et al.*, 1999). The dose of MDMA discriminated by rats and humans is identical: 1.5 mg/kg, i.p., for rats (Glennon and Higgs, 1992; Oberlender and Nichols, 1988; Schechter, 1988) and 1.5 mg/kg, p.o., for humans (Johanson *et al.*, 2005). A few studies have shown that rats will self-administer MDMA at doses ranging from 0.25 to 1.0 mg/kg i.v., indicating these doses possess reinforcing efficacy (Ratzenboeck *et al.*, 2001; Schenk *et al.*, 2003). Wakonigg *et al.* (2003) demonstrated that a single i.v. injection of 1 mg/kg MDMA serves as a powerful reinforcer in an operant runway procedure, and MDMA displays similar reinforcing potency in Sprague–Dawley and Long–Evans rat strains. Tancer and Johanson (2003) reported that 1 and 2 mg/kg of MDMA have reinforcing properties in humans which resemble those of (+)-amphetamine. The findings summarized in Table III suggest there is no scientific justification for using allometric scaling to “adjust” MDMA doses between rats and humans.

Based on this analysis, we devised an MDMA dosing regimen in rats which attempts to mimic binge use of MDMA in humans. Male Sprague–Dawley rats were double-housed in plastic cages, under conditions of constant ambient temperature (22 °C) and humidity (70%) in a vivarium. In our most recent studies, three i.p. injections of 1.5 or 7.5 mg/kg MDMA were administered, one dose every 2 h, to yield cumulative doses of 4.5 or 22.5 mg/kg (Baumann *et al.*, 2008a). Control rats received saline vehicle according to the same schedule. Rats were removed from their cages to receive i.p. injections, but were otherwise confined to their home cages. The 1.5 mg/kg dose was used as a low “behavioral” dose whereas the 7.5 mg/kg dose was used as a high “toxic” dose (i.e., a dose fivefold greater than threshold). Our repeated dosing regimen was designed to account for the common practice of sequential dosing (i.e., “bumping”) used by humans during rave parties (Parrott, 2002). During the binge dosing procedure, body temperatures were measured by a rectal thermometer probe, and 5-HT-mediated behaviors were scored for 6 h after the first dose. Rats were decapitated 2 weeks after dosing, brain regions were dissected, and tissue levels of 5-HT and DA were determined by HPLC-ECD as described previously (Baumann *et al.*, 2001).

Figure 6 demonstrates that our binge MDMA dosing regimen increases core body temperature in rats [$F_{2,105} = 218.11$, $P < 0.0001$]. Specifically, repeated i.p. doses of 7.5 mg/kg MDMA elicit persistent hyperthermia on the day of treatment, whereas doses of 1.5 mg/kg do not. The 7.5 mg/kg dose causes temperature increases which are about 2 °C above normal, and such elevations are present for at least 6 h. The data in Fig. 7 demonstrate that binge MDMA treatment significantly decreases tissue 5-HT levels in the n. accumbens [$F_{2,17} = 50.52$, $P < 0.0001$], striatum [$F_{2,17} = 25.49$, $P < 0.001$], and mediobasal hypothalamus [$F_{2,17} = 14.31$, $P < 0.0001$] when assessed 2 weeks later. *Post hoc* tests reveal that high-dose MDMA produces long-term depletions of tissue 5-HT (~50% reductions) in all three regions examined, but the low-dose group has 5-HT concentrations similar to saline controls. Transmitter depletion is selective for 5-HT neurons since tissue DA levels are unaffected. The magnitude of 5-HT depletions depicted in Fig. 7 is similar to that observed by others (Battaglia *et al.*, 1987; Schmidt, 1987; Stone *et al.*, 1987).

Given that high-dose MDMA binges cause acute hyperthermia and long-term 5-HT depletions in the same rats, we examined the relationship between body temperature and postmortem tissue monoamines using Pearson correlation analysis. We found that body temperature is negatively correlated with tissue 5-HT in the n. accumbens ($r = -0.8630$, $P < 0.0001$), striatum ($r = -0.8089$, $P < 0.0001$), and hypothalamus ($r = -0.6910$, $P < 0.001$). There are no significant correlations between body temperature and tissue DA. Figure 8 shows representative data from the n. accumbens, where MDMA-induced elevations in core temperature are significantly correlated with depletion of tissue 5-HT but not DA. Collectively, our findings demonstrate that repeated treatments with behaviorally relevant doses of MDMA do not cause acute hyperthermia or long-term 5-HT depletions. In contrast, repeated administration of MDMA at a dose which is fivefold higher than the behavioral dose causes both of these adverse effects. The degree of acute hyperthermia produced by MDMA appears to predict the extent of subsequent 5-HT depletion. Our findings are consistent with those of O'Shea *et al.* (1998) who reported that high-dose MDMA (10 or 15 mg/kg, i.p.), but not low-dose MDMA (4 mg/kg, i.p.), causes acute hyperthermia and long-term 5-HT depletion in Dark Agouti rats.

V. Functional Consequences of MDMA-Induced 5-HT Depletion

Any definition of neurotoxicity must include the concept that functional impairments accompany neuronal damage (Moser, 2000; Winneke and Lilienthal, 1992). As noted previously, high-dose MDMA causes persistent inactivation of tryptophan hydroxylase which leads to inhibition of 5-HT synthesis and loss of 5-HT (O'Hearn *et al.*, 1988; Stone *et al.*, 1987). Moreover, MDMA-induced reduction in the density of SERT binding sites leads to decreased capacity for 5-HT uptake in nervous tissue (Battaglia *et al.*, 1987; Schmidt, 1987). Regardless of whether these 5-HT deficits reflect neurotoxic damage or long-term adaptations, such changes would be expected to have discernible *in vivo* correlates. Many investigators have examined functional consequences of high-dose MDMA administration, and a comprehensive review of this subject is beyond the scope of this review (reviewed by Cole and Sumnall, 2003; Green *et al.*, 2003). The following discussion will consider long-term effects of MDMA (i.e., >1 week) on *in vivo* indicators of 5-HT function in rats as measured by electrophysiological recording, neuroendocrine secretion, microdialysis sampling, and specific behaviors. A number of key findings are summarized in Table IV. In general, few published studies have been able to relate the magnitude of MDMA-induced 5-HT depletion to the degree of specific functional impairment. Furthermore, MDMA administration rarely causes persistent changes in baseline measures of neural function, and deficits are most readily demonstrated by provocation of the 5-HT system by pharmacological (e.g., drug challenge) or physiological means (e.g., environmental stress).

5-HT projections innervating the rat forebrain have cell bodies residing in the raphe nuclei (Steinbusch, 1981). These neurons exhibit pacemaker-like electrical activity which can be recorded using electrophysiological techniques (Aghajanian *et al.*, 1978; Sprouse *et al.*, 1989). Gartside *et al.* (1996) used extracellular recording methods to examine 5-HT cell firing in the dorsal raphe of rats previously treated with MDMA. Rats received two daily injections of 20 mg/kg, s.c. MDMA for 4 days and were tested under chloral hydrate anesthesia 2 weeks later. MDMA pretreatment had no effect on the number of classical or burst-firing 5-HT cells encountered during recording. Additionally, 5-HT cell firing rates and action potential characteristics were not different between MDMA- and saline-pretreated groups. These data show that 5-HT neurons and their firing properties are not altered after MDMA administration, and this agrees with immunohistochemical evidence demonstrating MDMA does not destroy 5-HT perikarya. The electrophysiological data from MDMA-pretreated rats differ from the findings reported with 5,7-DHT. In rats treated with i.c.v. 5,7-DHT, the number of classical and burst-firing 5-HT neurons is dramatically decreased in the dorsal raphe, in conjunction with a loss of 5-HT fluorescence (Aghajanian *et al.*, 1978; Hajos and Sharp, 1996). Thus, 5,7-DHT produces reductions in 5-HT cell firing that are attributable to cell death, but MDMA does not.

5-HT neurons projecting from raphe nuclei to the hypothalamus provide stimulatory input for the secretion of adrenocorticotropin (ACTH) and prolactin from the anterior pituitary (Van de Kar, 1991). Accordingly, 5-HT releasers (e.g., fenfluramine) and 5-HT receptor agonists increase plasma levels of these pituitary hormones in rats and humans, while stimulating glucocorticoid secretion from the adrenals of both species (reviewed by Levy *et al.*, 1994). Neuroendocrine challenge experiments have been used to demonstrate changes in serotonergic responsiveness in rats treated with MDMA (Poland, 1990; Poland *et al.*, 1997; Series *et al.*, 1995). In the most comprehensive study, Poland *et al.* (1997) examined effects of high-dose MDMA on hormone responses elicited by acute fenfluramine challenge. Male Sprague–Dawley rats received single s.c. injections of 20 mg/kg MDMA and were tested 2 weeks later. Prior MDMA exposure did not alter baseline levels of circulating ACTH or prolactin. However, in MDMA-pretreated rats, fenfluramine-induced ACTH secretion was reduced while prolactin secretion was enhanced. The MDMA dosing regimen caused significant depletions of tissue 5-HT in various brain regions, including hypothalamus. In a follow-up time-course study, rats received twice daily s.c. injections of 20 mg/kg MDMA for 4 days, and were challenged with fenfluramine (6 mg/kg, s.c.) at 4, 8, and 12 months thereafter. As observed in the single dose MDMA study, rats exposed to multiple MDMA doses displayed blunted ACTH responses and augmented prolactin responses to fenfluramine. Interestingly, the impaired ACTH response persisted for 12 months in MDMA-pretreated rats, even though tissue levels of 5-HT were not depleted at this time point. The data show that high-dose MDMA can cause functional abnormalities for up to 1 year, and changes in 5-HT responsiveness do not necessarily parallel the extent of recovery from 5-HT depletions in brain.

In our laboratory, we wished to further explore the long-term neuroendocrine consequences of MDMA exposure. Specifically, we wished to compare MDMA-induced hormone responses in rats pretreated with low- versus high-dose MDMA binges. Utilizing the MDMA dosing regimen described previously, male rats received three i.p. injections of 1.5 or 7.5 mg/kg MDMA, one dose every 2 h. Control rats received saline vehicle according to the same schedule. One week after MDMA binges, rats were fitted with indwelling jugular catheters under pentobarbital anesthesia. One week after surgery (i.e., 2 weeks after MDMA or saline), rats were brought into the testing room, and i.v. catheters were connected to extension tubes. Rats received i.v. injections of 1 mg/kg MDMA at time zero, followed by 3 mg/kg MDMA 60 min later. Blood samples were withdrawn via the catheters immediately before and at 15, 30, and 60 min after each dose of MDMA. Elements of the 5-HT

syndrome, namely forepaw treading, flattened body posture, and head weaving, were scored during the blood sampling procedure. Plasma levels of prolactin and corticosterone were measured by double-antibody radioimmunoassay methods (Baumann *et al.*, 1998, 2008a).

Figure 9 shows the effects of acute i.v. MDMA on prolactin and corticosterone secretion in rats exposed to MDMA binges. MDMA pretreatment does not alter baseline levels of either hormone. Acute i.v. administration of MDMA elicits dose-related elevations in circulating prolactin and corticosterone, in agreement with the findings of others who administered MDMA to rats via the i.p. route (Nash *et al.*, 1988). Importantly, MDMA pretreatment significantly influences the magnitude of MDMA-induced prolactin [$F_{2,147} = 21.03$, $P < 0.0001$] and corticosterone [$F_{2,147} = 12.20$, $P < 0.001$] responses. *Post hoc* tests reveal that rats exposed to 7.5 mg/kg MDMA binges display reductions in prolactin and corticosterone secretion evoked by MDMA challenge. Blunted endocrine sensitivity is most severe for prolactin secretion, where responses in the high-dose binge group are about 50–60% lower than control responses. It is noteworthy that MDMA-induced endocrine secretion is similar between the low-dose binge group and saline-pretreated controls. Figure 10 shows the effects of MDMA challenge on 5-HT syndrome in rats previously exposed to MDMA binges. Acute i.v. MDMA produces robust 5-HT syndrome that is significantly affected by MDMA pretreatment [$F_{2,42} = 8.15$, $P < 0.001$]. Specifically, rats pretreated with high-dose binges display blunted syndrome scores after 3 mg/kg i.v. MDMA. Similar to the neuroendocrine findings, the behavioral effects of MDMA in the low-dose binge group are comparable to saline-pretreated controls.

Our neuroendocrine and behavioral results are consistent with the development of tolerance to pharmacological effects of MDMA. The present endocrine data do not agree completely with the data of Poland *et al.* (1997); however, our findings do agree with previous data showing blunted hormonal responses to fenfluramine in rats previously treated with high-dose fenfluramine (Baumann *et al.*, 1998). Perhaps more importantly, the data shown in Fig. 9 are strikingly similar to clinical findings in which cortisol and prolactin responses to acute (+)-fenfluramine administration are reduced in human MDMA users (Gerra *et al.*, 1998, 2000; Gouzoulis-Mayfrank *et al.*, 2002). Indeed, Gerra *et al.* (2000) reported that (+)-fenfluramine-induced prolactin secretion is blunted in abstinent MDMA users for up to 1 year after cessation of drug use. The mechanism(s) underlying reduced sensitivity to (+)-fenfluramine and MDMA are not known, but it is tempting to speculate that MDMA-induced impairments in evoked 5-HT release are involved. While some investigators have cited neuroendocrine changes in human MDMA users as evidence for 5-HT neurotoxicity, Gouzoulis-Mayfrank *et al.* (2002) provide a compelling argument that endocrine abnormalities in MDMA users could be related to cannabis use rather than MDMA. Further experiments will be required to resolve the precise nature of neuroendocrine changes in human MDMA users.

In vivo microdialysis allows continuous sampling of extracellular fluid from intact brain, and this method has been used to evaluate persistent neurochemical consequences of MDMA exposure (Gartside *et al.*, 1996; Matuszewich *et al.*, 2002; Series *et al.*, 1994; Shankaran and Gudelsky, 1999). For example, Shankaran and Gudelsky (1999) assessed neurochemical effects of acute MDMA challenge in rats that had previously received four i.p. injections of 10 mg/kg MDMA. *In vivo* microdialysis was performed in the striatum of conscious rats 1 week after high-dose MDMA treatment. Baseline levels of dialysate 5-HT were not altered by prior MDMA exposure even though tissue levels of 5-HT in striatum were depleted by 50%. The ability of MDMA to evoke 5-HT release was severely impaired in MDMA-pretreated rats, while the concurrent DA response was normal. In this same study, effects of MDMA on body temperature and 5-HT syndrome were attenuated in MDMA-pretreated rats, suggesting the development of tolerance. Other investigations using *in vivo*

microdialysis methods have shown that 5-HT release in response to physiological or stressful stimuli is impaired in rats pretreated with high-dose MDMA (Gartside *et al.*, 1996; Matuszewich *et al.*, 2002).

Based on our neuroendocrine and behavioral findings, we sought to evaluate whether MDMA tolerance might be reflective of neurochemical changes in the brain. To this end, we performed *in vivo* microdialysis in the n. accumbens and striatum of rats previously exposed to low- and high-dose MDMA binges. For these experiments, rats received three i.p. injections of 1.5 or 7.5 mg/kg MDMA, one dose every 2 h. Control rats received saline vehicle according to the same schedule. One week after MDMA binges, rats were fitted with indwelling jugular catheters and intracranial guide cannulae under pentobarbital anesthesia. Guide cannulae were aimed at the n. accumbens or striatum in separate groups of rats. One week after surgery (i.e., 2 weeks after MDMA or saline), rats were subjected to microdialysis testing. Dialysate samples were collected at 20 min intervals and assayed for 5-HT and DA by HPLC-ECD. After three baseline samples were obtained, rats received i.v. injections of 1 mg/kg MDMA at time zero, followed by 3 mg/kg MDMA 60 min later. Dialysate samples were collected until 1 h after the second dose of MDMA.

Figure 11 illustrates the effects of i.v. MDMA injections on 5-HT and DA release in the n. accumbens of rats previously exposed to MDMA binges. MDMA pretreatment does not affect baseline concentration of either transmitter. Acute i.v. MDMA produces dose-related elevations in dialysate 5-HT and DA, consistent with our prior findings (Baumann *et al.*, 2005, 2007). However, MDMA pretreatment significantly affects dialysate 5-HT responsiveness [$F_{2,161} = 22.95$, $P < 0.0001$], with rats in the 7.5 mg/kg MDMA group displaying reductions in evoked 5-HT release. The magnitude of 5-HT responses in the high-dose MDMA group is about half that of responses in the saline-pretreated group at both challenge doses of MDMA. Rats in the 1.5 mg/kg MDMA group exhibit 5-HT release that is nearly identical to saline-pretreated controls. Interestingly, MDMA pretreatment has no effect on dialysate DA responsiveness. In this case, rats from all pretreatment groups exhibit similar DA release in response to MDMA challenge injections. Microdialysis findings from the striatum gave results analogous to those from n. accumbens. Namely, rats pretreated with high-dose MDMA binges have impairments in MDMA-induced release of 5-HT but not DA.

Taken together with previous studies, our microdialysis data reveal important long-term consequences of MDMA administration: (1) baseline concentrations of dialysate 5-HT are not altered, despite profound depletions of tissue transmitter, (2) evoked 5-HT release is blunted in response to pharmacological or physiological provocation, (3) impairments in transmitter release are selective for 5-HT since evoked DA release is not affected, and (4) blunted 5-HT release may underlie tolerance to various pharmacological effects of MDMA. The dialysis findings with MDMA resemble those obtained from rats treated with 5-HT neurotoxin, 5,7-dihydroxytryptamine (5,7-DHT) (Hall *et al.*, 1999; Kirby *et al.*, 1995; Romero *et al.*, 1998). In a representative study, Kirby *et al.* (1995) used microdialysis in rat striatum to evaluate the long-term neurochemical effects of i.c.v. 5,7-DHT. These investigators showed that impairments in stimulated 5-HT release and reductions in dialysate 5-HIAA are highly correlated with loss of tissue 5-HT, whereas baseline dialysate 5-HT is not. In fact, depletions of brain tissue 5-HT up to 90% did not affect baseline levels of dialysate 5-HT (Kirby *et al.*, 1995). It seems that adaptive mechanisms serve to maintain normal concentrations of synaptic 5-HT, even under conditions of severe transmitter depletion. A comparable situation exists after lesions of the nigrostriatal DA system where baseline levels of extracellular DA are maintained in the physiological range despite substantial loss of tissue DA (see Zigmond *et al.*, 1990). In the case of high-dose MDMA treatment, it seems feasible that reductions in 5-HT uptake (e.g., less functional SERT

protein) and metabolism (e.g., decreased monoamine oxidase activity) compensate for 5-HT depletions in order to keep optimal concentrations of 5-HT bathing nerve cells. On the other hand, deficits in 5-HT release are readily demonstrated in MDMA-pretreated rats when 5-HT systems are taxed by drug challenge or environmental stressors. It is noteworthy that human MDMA users often report tolerance as a major side-effect of chronic drug use (Parrott, 2005; Verheyden *et al.*, 2003). The rat data shown here suggest the possibility that MDMA tolerance in humans may reflect deficits in central 5-HT release mechanisms.

One of the more serious and disturbing clinical findings is that MDMA causes persistent cognitive deficits in some users (Morgan, 2000; Reneman, 2003). Numerous research groups have examined the effects of MDMA treatment on learning and memory processes in rats, yet most studies failed to identify persistent impairments—even when extensive 5-HT depletions were present (Byrne *et al.*, 2000; McNamara *et al.*, 1995; Ricaurte *et al.*, 1993; Robinson *et al.*, 1993; Seiden *et al.*, 1993; Slikker *et al.*, 1989). While a complete review of this literature is not possible, representative findings will be mentioned. In an extensive series of experiments, Seiden *et al.* (1993) evaluated the effects of high-dose MDMA on a battery of tests including open-field behavior, schedule-controlled behavior, one-way avoidance, discriminated two-way avoidance, forced swim, and radial maze performance. Male Sprague–Dawley rats received twice daily s.c. injections of 10–40 mg/kg MDMA for 4 days, and were tested beginning 2 weeks after treatment. Despite large depletions of brain tissue 5-HT, MDMA-pretreated rats exhibited normal behaviors in all paradigms. Likewise, Robinson *et al.* (1993) found that MDMA-induced depletion of cortical 5-HT up to 70% did not alter spatial navigation, skilled forelimb use or foraging behavior in rats. On the other hand, Marston *et al.* (1999) reported that MDMA administration produces persistent deficits in a delayed nonmatch to performance (DNMTP) procedure when long delay intervals are employed (i.e., 30 s). Specifically, saline-pretreated rats exhibited progressive improvement in task performance over successive days of testing, whereas MDMA-pretreated rats did not. The authors theorized that delay-dependent impairments in the DNMTP procedure reflect MDMA-induced deficits in short-term memory, possibly attributable to 5-HT depletion.

With the exception of the findings of Marston *et al.*, the collective behavioral data in rats indicate that MDMA-induced depletions of brain 5-HT have little effect on cognitive processes. There are several potential explanations for this apparent paradox. First, high-dose MDMA administration produces only partial depletion of 5-HT in the range of 40–60% in most brain areas. This level of 5-HT loss may not be sufficient to elicit behavioral alterations, as compensatory adaptations in 5-HT neurons could maintain normal physiological function. Second, MDMA appears to selectively affect fine-diameter fibers arising from the dorsal raphe, and it is possible that these 5-HT circuits may not subserve the behaviors being monitored. Third, the behavioral tests utilized in rat studies might not be sensitive enough to detect subtle changes in learning and memory processes. Finally, the functional reserve capacity in the CNS might be sufficient to compensate for even large depletions of a single transmitter.

While MDMA appears to have few long-term effects on cognition in rats, a growing body of evidence demonstrates that MDMA administration can cause persistent anxiety-like behaviors in this species (Fone *et al.*, 2002; Gurtman *et al.*, 2002; Morley *et al.*, 2001). Morley *et al.* (2001) first reported that MDMA exposure induces long-term anxiety in rats. These investigators gave male Wistar rats one or four i.p. injections of 5 mg/kg MDMA for 2 consecutive days. Subjects were tested 3 months later in a battery of anxiety-related paradigms including elevated plus maze, emergence and social interaction tests. Rats receiving either single or multiple MDMA injections displayed marked increases in anxiogenic behaviors in all three tests when compared to control rats. Because no 5-HT endpoints were examined, it was impossible to relate changes in behavior to changes in 5-

HT transmission. In a follow-up study, Gurtman *et al.* (2002) replicated the original findings of Morley *et al.* using rats pretreated with four i.p. injections of 5 mg/kg MDMA for 2 days; persistent anxiogenic effects of MDMA were associated with depletions of 5-HT in the amygdala, hippocampus, and striatum. Interestingly, Fone *et al.* (2002) showed that twice daily injections of 7.5 mg/kg MDMA for 3 days caused impairments in social interaction in adolescent Lister rats, even in the absence of 5-HT depletions or reductions in [³H]-paroxetine-labeled SERT binding sites. These data suggested the possibility that MDMA-induced anxiety does not require 5-HT deficits.

In an attempt to determine potential mechanisms underlying MDMA-induced anxiety, McGregor *et al.* (2003) evaluated effects of the drug on anxiety-related behaviors and a number of postmortem parameters including autoradiography for SERT and 5-HT receptor subtypes. Rats received moderate (5 mg/kg, i.p., 2 days) or high (5 mg/kg, i.p., 4 injections, 2 days) doses of MDMA, and tests were conducted 10 weeks later. This study confirmed that moderate doses of MDMA can cause protracted increases in anxiety-like behaviors without significant 5-HT depletions. Furthermore, the autoradiographic analysis revealed that anxiogenic effects of MDMA may involve long-term reductions in 5-HT_{2A/2C} receptors rather than reductions in SERT binding. Additional work by Bull *et al.* (2003, 2004) suggests that decreases in the sensitivity of 5-HT_{2A} receptors, but not 5-HT_{2C} receptors, could underlie MDMA-associated anxiety. Clearly, more investigation into this important area of research is warranted.

VI. Reversal of MDMA-Induced 5-HT Depletion by L-5-Hydroxytryptophan

As noted in Section I, accumulating evidence indicates that long-term MDMA abuse is associated with cognitive impairments and mood disturbances that can last for months after cessation of drug intake (Morgan, 2000; Parrott, 2002). There is speculation that psychological problems in MDMA users may result from 5-HT depletions in the CNS (McCann *et al.*, 2008). To the extent that MDMA might produce 5-HT depletion in humans, one feasible approach for treatment would be to restore brain 5-HT by administration of the 5-HT precursor L-5-hydroxytryptophan (5-HTP). To test this idea, male Sprague–Dawley rats received three i.p. injections of 7.5 mg/kg MDMA or saline, one dose every 2 h (Wang *et al.*, 2007). Two weeks later, rats received i.p. injections of saline or 5-HTP plus benserazide (5-HTP-B), each drug at 50 mg/kg. Rats were sacrificed 2 h after treatments. Benserazide is an inhibitor of aromatic acid decarboxylase which prevents peripheral conversion of 5-HTP to 5-HT, thereby facilitating entry of 5-HTP into the CNS. Previous studies show that a similar 5-HTP-B dosing regimen produces large increases in extracellular 5-HT in rat n. accumbens (Halladay *et al.*, 2006). 5-HT concentrations in brain tissue sections were visualized using immunohistochemistry. As reported in Fig. 12, MDMA markedly decreases immunoreactive 5-HT in the caudate n. and hippocampus to about 35% of control. Under the same dosing conditions, SERT binding in these brain regions is reduced by nearly 90%. Importantly, administration of 5-HTP-B to MDMA-pretreated rats significantly increases the 5-HT signal toward normal levels in caudate (85% of control) and hippocampus (66% of control). These experiments suggest that high-dose MDMA treatments leave 5-HT nerve terminals largely intact but emptied of endogenous 5-HT. Administration of the 5-HT precursor 5-HTP appears to “refill” empty nerve terminals, substantially restoring brain 5-HT levels. Our data suggest that precursor loading with 5-HTP might be a clinically useful approach to treatment in abstinent MDMA users who experience cognitive and psychiatric morbidity due to persistent 5-HT deficits (Thomasius *et al.*, 2006). Future investigations should test the validity of this hypothesis in carefully controlled clinical studies.

VII. MDMA and Valvular Heart Disease

Recent evidence indicates that MDA, the *N*-demethylated metabolite of MDMA, displays direct agonist actions at the 5-HT_{2B} receptor subtype (Setola *et al.*, 2003). This finding suggests that illicit MDMA use might increase the risk for VHD. Understanding the possible relationship between MDMA and VHD is best understood in the context of fenfluramine-associated valvulopathy. (±)-Fenfluramine, and its more potent enantiomer, (+)-fenfluramine, were commonly prescribed anorectic medications. These agents were removed from clinical use in 1997 due to the occurrence of VHD in some patients (Connolly and McGoon, 1999). Although a serotonergic mechanism was suspected as a possible cause of the VHD (Connolly *et al.*, 1997), little was known about the pathogenesis of this adverse effect in the late 1990s. In light of the established role of 5-HT as a mitogen (Seuwen *et al.*, 1988), we carried out an investigation to determine if isomers of fenfluramine or its metabolites (i.e., norfenfluramines), might activate a specific mitogenic 5-HT receptor subtype (Rothman *et al.*, 2000). Drugs were tested for activity at various 5-HT receptor sites using high-throughput binding and functional assays. A number of additional test drugs were included in our study to provide both positive and negative controls. “Positive control” drugs included methysergide, its active metabolite methylergonovine (Bredberg *et al.*, 1986) and ergotamine. Methysergide and ergotamine are known to produce left-sided VHD chiefly affecting the mitral valve (Bana *et al.*, 1974; Hendriks *et al.*, 1996). “Negative control” drugs included phentermine, fluoxetine, and its metabolite norfluoxetine. These drugs interact with monoamine transporters but are not associated with VHD. Our working hypothesis was that “positive control” drugs would share in common the ability to activate a mitogenic 5-HT receptor expressed in heart valves, whereas “negative control” drugs would not.

An initial receptorome screen (Setola and Roth, 2005) led to a detailed evaluation of the binding of these drugs to the 5-HT₂ family of receptors. Our data reveal that isomers of fenfluramine display low affinity for most 5-HT receptors. In contrast, isomers of norfenfluramine possess high affinity ($K_i = 10\text{--}50\text{ nM}$) for the 5-HT_{2B} receptor subtype, confirming the findings of others (Fitzgerald *et al.*, 2000; Porter *et al.*, 1999). Moreover, functional studies demonstrate that norfenfluramines are full agonists at the 5-HT_{2B} site. Positive control drugs such as ergotamine, methysergide, and methylergonovine are partial agonists at the 5-HT_{2B} receptor, whereas negative control drugs are not. Taken together, our *in vitro* findings indicate that 5-HT_{2B} receptors are involved in the valvulopathic effects of fenfluramine. Consistent with this hypothesis, 5-HT_{2B} receptors are richly expressed on mitral and aortic valves (Fitzgerald *et al.*, 2000), where they can stimulate mitogenesis (Lopez-Illasaca, 1998).

The importance of 5-HT_{2B} receptors in mediating drug-induced VHD is supported by recent data showing carbergoline and pergolide are potent agonists at this receptor site. Both of these medications are known to increase the risk of VHD (for review see Roth, 2007). As noted earlier, Setola *et al.* have reported that MDMA and MDA are 5-HT_{2B} receptor agonists that elicit prolonged mitogenic responses in human valvular interstitial cells via activation of 5-HT_{2B} receptors (Setola *et al.*, 2003). The data summarized in Table V demonstrate that stereoisomers of MDA are particularly potent and efficacious agonists at the 5-HT_{2B} site. The *in vitro* findings predict that MDMA abuse might cause VHD, similar to the effects of other known 5-HT_{2B} agonists. Indeed, a recent clinical investigation reported that MDMA users have markedly increased valvular regurgitation compared to normal control subjects (Droogmans *et al.*, 2007). The severity of regurgitation was directly related to the amount of MDMA consumed, indicating a dose-related increase in the risk for VHD. Additional studies will be needed to confirm and extend these important clinical observations.

VIII. Summary

The findings reviewed in this chapter allow a number of conclusions to be drawn with regard to MDMA-induced toxic effects. First, MDMA produces pharmacological actions at the same doses in rats and humans (e.g., 1–2 mg/kg), which argues against the arbitrary use of allometric scaling to adjust doses between these species. Second, high doses of MDMA that produce 5-HT depletions in rats are accompanied by impairments in evoked 5-HT release that are manifest as drug tolerance. The animal data indicate that tolerance in human MDMA users could reflect central 5-HT dysfunction, thereby contributing to dangerous dose escalation. Third, doses of MDMA that fail to cause 5-HT depletions in rats can produce persistent increases in anxiety-like behaviors, suggesting even moderate doses of the drug may pose risks. Finally, the agonist activity of MDA isomers at the 5-HT_{2B} receptor subtype could be involved with the increased risk for VHD in heavy MDMA users. Future investigations are warranted to further elucidate the long-term effects of MDMA exposure on neural and cardiac function in humans.

Acknowledgments

This research was generously supported by the NIDA IRP. The authors are indebted to John Partilla, Chris Dersch, Mario Ayestas, Robert Clark, Fred Franken, and John Rutter for their expert technical assistance during these studies.

References

- Aghajanian GK, Wang RY, Baraban J. Serotonergic and non-serotonergic neurons of the dorsal raphe: Reciprocal changes in firing induced by peripheral nerve stimulation. *Brain Res.* 1978; 153(1):169–175. [PubMed: 679043]
- Bana DS, MacNeal PS, LeCompte PM, Shah Y, Graham JR. Cardiac murmurs and endocardial fibrosis associated with methysergide therapy. *Am. Heart J.* 1974; 88:640–655. [PubMed: 4420941]
- Banken JA. Drug abuse trends among youth in the United States. *Ann. NY Acad. Sci.* 2004; 1025:465–471. [PubMed: 15542750]
- Bankson MG, Cunningham KA. 3,4-Methylenedioxymethamphetamine (MDMA) as a unique model of serotonin receptor function and serotonin-dopamine interactions. *J. Pharmacol. Exp. Ther.* 2001; 297:846–852. [PubMed: 11356903]
- Battaglia G, De Souza EB. Pharmacologic profile of amphetamine derivatives at various brain recognition sites: Selective effects on serotonergic systems. *NIDA Res. Monogr.* 1989; 94:240–258. [PubMed: 2514364]
- Battaglia G, Yeh SY, O'Hearn E, Molliver ME, Kuhar MJ, De Souza EB. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: Quantification of neurodegeneration by measurement of [³H]paroxetine-labeled serotonin uptake sites. *J. Pharmacol. Exp. Ther.* 1987; 242:911–916. [PubMed: 2443644]
- Battaglia G, Yeh SY, De Souza EB. MDMA-induced neurotoxicity: Parameters of degeneration and recovery of brain serotonin neurons. *Pharmacol. Biochem. Behav.* 1988; 29:269–274. [PubMed: 2452449]
- Baumann, MH.; Rutter, JJ. Application of *in vivo* microdialysis methods to the study of psychomotor stimulant drugs. In: Waterhouse, BD., editor. *Methods in Drug Abuse Research, Cellular and Circuit Analysis*. Boca Raton, FL: CRC Press; 2003. p. 51-86.
- Baumann MH, Ayestas MA, Rothman RB. Functional consequences of central serotonin depletion produced by repeated fenfluramine administration in rats. *J. Neurosci.* 1998; 18:9069–9077. [PubMed: 9787010]
- Baumann MH, Ayestas MA, Dersch CM, Rothman RB. 1-(*m*-Chlorophenyl) piperazine (mCPP) dissociates *in vivo* serotonin release from long-term serotonin depletion in rat brain. *Neuropsychopharmacology.* 2001; 24:492–501. [PubMed: 11282249]

- Baumann MH, Clark RD, Budzynski AG, Partilla JS, Blough BE, Rothman RB. N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy'). *Neuropsychopharmacology*. 2005; 30(3):550–560. [PubMed: 15496938]
- Baumann MH, Wang X, Rothman RB. 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: A reappraisal of past and present findings. *Psychopharmacology (Berl.)*. 2007; 189(4):407–424. [PubMed: 16541247]
- Baumann MH, Clark RD, Franken FH, Rutter JJ, Rothman RB. Tolerance to 3,4-methylenedioxymethamphetamine in rats exposed to single high-dose binges. *Neuroscience*. 2008a; 152(3):773–784. [PubMed: 18313226]
- Baumann MH, Clark RD, Rothman RB. Locomotor stimulation produced by 3,4-methylenedioxymethamphetamine (MDMA) is correlated with dialysate levels of serotonin and dopamine in rat brain. *Pharmacol. Biochem. Behav.* 2008b; 90(2):208–217. [PubMed: 18403002]
- Baumgarten HG, Lachenmayer L. Serotonin neurotoxins—Past and present. *Neurotox. Res.* 2004; 6(7–8):589–614. [PubMed: 15639791]
- Benmansour S, Cecchi M, Morilak DA, Gerhardt GA, Javors MA, Gould GG, Frazer A. Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. *J. Neurosci.* 1999; 19(23):10494–10501. [PubMed: 10575045]
- Berger UV, Gu XF, Azmitia EC. The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, *p*-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. *Eur. J. Pharmacol.* 1992; 215:153–160. [PubMed: 1356787]
- Bredberg U, Eyjolfsson GS, Paalzow L, Tfelt-Hansen P, Tfelt-Hansen V. Pharmacokinetics of methysergide and its metabolite methylergometrine in man. *Eur. J. Clin. Pharmacol.* 1986; 30:75–77. [PubMed: 3709634]
- Bull EJ, Hutson PH, Fone KC. Reduced social interaction following 3,4-methylenedioxymethamphetamine is not associated with enhanced 5-HT_{2C} receptor responsivity. *Neuropharmacology*. 2003; 44(4):439–448. [PubMed: 12646281]
- Bull EJ, Hutson PH, Fone KC. Decreased social behaviour following 3,4-methylenedioxymethamphetamine (MDMA) is accompanied by changes in 5-HT_{2A} receptor responsivity. *Neuropharmacology*. 2004; 46(2):202–210. [PubMed: 14680758]
- Byrne T, Baker LE, Poling A. MDMA and learning: Effects of acute and neurotoxic exposure in the rat. *Pharmacol. Biochem. Behav.* 2000; 66(3):501–508. [PubMed: 10899362]
- Carlsson A. The contribution of drug research to investigating the nature of endogenous depression. *Pharmakopsychiatr. Neuropsychopharmacol.* 1976; 9(1):2–10. [PubMed: 10584]
- Charlier C, Broly F, Lhermitte M, Pinto E, Ansseau M, Plomteux G. Polymorphisms in the CYP 2D6 gene: Association with plasma concentrations of fluoxetine and paroxetine. *Ther. Drug Monit.* 2003; 25(6):738–742. [PubMed: 14639062]
- Chu T, Kumagai Y, DiStefano EW, Cho AK. Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion. *Biochem. Pharmacol.* 1996; 51(6):789–796. [PubMed: 8602874]
- Colado MI, O'Shea E, Green AR. Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function. *Psychopharmacology (Berl.)*. 2004; 173(3–4):249–263. [PubMed: 15083264]
- Cole JC, Sumnall HR. The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA). *Neurosci. Biobehav. Rev.* 2003; 27(3):199–217. [PubMed: 12788333]
- Commings DL, Vosmer G, Virus RM, Woolverton WL, Schuster CR, Seiden LS. Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. *J. Pharmacol. Exp. Ther.* 1987; 241(1):338–345. [PubMed: 2883295]
- Connolly HM, McGoon MD. Obesity drugs and the heart. *Curr. Probl. Cardiol.* 1999; 24:745–792. [PubMed: 10609092]

- Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Schaff HV. Valvular heart disease associated with fenfluramine-phentermine. *N. Engl. J. Med.* 1997; 337(9):581–588. [PubMed: 9271479]
- Crespi D, Mennini T, Gobbi M. Carrier-dependent and Ca(2+)-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylenedioxymethamphetamine, p-chloroamphetamine and (+)-fenfluramine. *Br. J. Pharmacol.* 1997; 121:1735–1743. [PubMed: 9283711]
- Dafters RI. Hyperthermia following MDMA administration in rats: Effects of ambient temperature, water consumption, and chronic dosing. *Physiol. Behav.* 1995; 58(5):877–882. [PubMed: 8577883]
- Dafters RI, Lynch E. Persistent loss of thermoregulation in the rat induced by 3,4-methylenedioxymethamphetamine (MDMA or “Ecstasy”) but not by fenfluramine. *Psychopharmacology (Berl.)*. 1998; 138(2):207–212. [PubMed: 9718291]
- de la Torre R, Farre M, Ortuno J, Mas M, Brenneisen R, Roset PN, Segura J, Cami J. Non-linear pharmacokinetics of MDMA (‘ecstasy’) in humans. *Br. J. Clin. Pharmacol.* 2000; 49:104–109. [PubMed: 10671903]
- de la Torre R, Farre M, Roset PN, Pizarro N, Abanades S, Segura M, Segura J, Cami J. Human pharmacology of MDMA: Pharmacokinetics, metabolism, and disposition. *Ther. Drug Monit.* 2004; 26(2):137–144. [PubMed: 15228154]
- Doblin R. A clinical plan for MDMA (Ecstasy) in the treatment of posttraumatic stress disorder (PTSD): Partnering with the FDA. *J. Psychoactive Drugs.* 2002; 34(2):185–194. [PubMed: 12691208]
- Drögmans S, Cosyns B, D’Haenen H, Creten E, Weytjens C, Franken PR, Scott B, Schoors D, Kemdem A, Close L, Vandenbossche JL, Bechet S, et al. Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. *Am. J. Cardiol.* 2007; 100(9):442–445. [PubMed: 17659925]
- Escobedo I, O’Shea E, Orio L, Sanchez V, Segura M, de la Torre R, Farre M, Green AR, Colado MI. A comparative study on the acute and long-term effects of MDMA and 3,4-dihydroxymethamphetamine (HHMA) on brain monoamine levels after i.p. or striatal administration in mice. *Br. J. Pharmacol.* 2005; 144(2):231–241. [PubMed: 15665862]
- Finnegan KT, Ricaurte GA, Ritchie LD, Irwin I, Peroutka SJ, Langston JW. Orally administered MDMA causes a long-term depletion of serotonin in rat brain. *Brain Res.* 1988; 447:141–144. [PubMed: 2898273]
- Fitzgerald JL, Reid JJ. Interactions of methylenedioxymethamphetamine with monoamine transmitter release mechanisms in rat brain slices. *Naunyn. Schmiedeberg Arch. Pharmacol.* 1993; 347(3):313–323. [PubMed: 8097569]
- Fitzgerald JL, Reid JJ. Sympathomimetic actions of methylenedioxymethamphetamine in rat and rabbit isolated cardiovascular tissues. *J. Pharm. Pharmacol.* 1994; 46:826–832. [PubMed: 7699571]
- Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, Sun JH, Link JR, Abbaszade I, Hollis JM, Largent BL, Hartig PR, et al. Possible role of valvular serotonin 5-HT_{2B} receptors in the cardiopathy associated with fenfluramine. *Mol. Pharmacol.* 2000; 57:75–81. [PubMed: 10617681]
- Fone KC, Beckett SR, Topham IA, Swettenham J, Ball M, Maddocks L. Long-term changes in social interaction and reward following repeated MDMA administration to adolescent rats without accompanying serotonergic neurotoxicity. *Psychopharmacology (Berl.)*. 2002; 159(4):437–444. [PubMed: 11823897]
- Forsling ML, Fallon JK, Shah D, Tilbrook GS, Cowan DA, Kicman AT, Hutt AJ. The effect of 3,4-methylenedioxymethamphetamine (MDMA, ‘Ecstasy’) and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus. *Br. J. Pharmacol.* 2002; 135(3):649–656. [PubMed: 11834612]
- Frazer A, Benmansour S. Delayed pharmacological effects of antidepressants. *Mol. Psychiatry.* 2002; 7 Suppl. 1:S23–S28. [PubMed: 11986992]

- Gartside SE, McQuade R, Sharp T. Effects of repeated administration of 3,4-methylenedioxymethamphetamine on 5-hydroxytryptamine neuronal activity and release in the rat brain *in vivo*. *J. Pharmacol. Exp. Ther.* 1996; 279(1):277–283. [PubMed: 8859004]
- Gerra G, Zaimovic A, Giucastro G, Maestri D, Monica C, Sartori R, Caccavari R, Delsignore R. Serotonergic function after (+/-)3,4-methylene-dioxymethamphetamine ('Ecstasy') in humans. *Int. Clin. Psychopharmacol.* 1998; 13(1):1–9. [PubMed: 9988361]
- Gerra G, Zaimovic A, Ferri M, Zambelli U, Timpano M, Neri E, Marzocchi GF, Delsignore R, Brambilla F. Long-lasting effects of (+/-)3,4-methylenedioxymethamphetamine (ecstasy) on serotonin system function in humans. *Biol. Psychiatry.* 2000; 47(2):127–136. [PubMed: 10664829]
- Geyer MA. Serotonergic functions in arousal and motor activity. *Behav. Brain Res.* 1996; 73(1–2):31–35. [PubMed: 8788473]
- Glennon RA, Higgs R. Investigation of MDMA-related agents in rats trained to discriminate MDMA from saline. *Pharmacol. Biochem. Behav.* 1992; 43(3):759–763. [PubMed: 1360162]
- Gold LH, Koob GF, Geyer MA. Stimulant and hallucinogenic behavioral profiles of 3,4-methylenedioxymethamphetamine and N-ethyl-3,4-methylenedioxyamphetamine in rats. *J. Pharmacol. Exp. Ther.* 1988; 247(2):547–555. [PubMed: 2903234]
- Goodwin JS, Larson GA, Swant J, Sen N, Javitch JA, Zahniser NR, De Felice LJ, Khoshbouei H. Amphetamine and methamphetamine differentially affect dopamine transporters *in vitro* and *in vivo*. *J. Biol. Chem.* 2008; 284(5):2978–2989. [PubMed: 19047053]
- Gouzoulis-Mayfrank E, Becker S, Pelz S, Tuchtenhagen F, Daumann J. Neuroendocrine abnormalities in recreational ecstasy (MDMA) users: Is it ecstasy or cannabis? *Biol. Psychiatry.* 2002; 51(9):766–769. [PubMed: 11983191]
- Green AR, Mehan AO, Elliott JM, O'Shea E, Colado MI. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). *Pharmacol. Rev.* 2003; 55(3):463–508. [PubMed: 12869661]
- Green AR, O'Shea E, Colado MI. A review of the mechanisms involved in the acute MDMA (Ecstasy)-induced hyperthermic response. *Eur. J. Pharmacol.* 2004; 500(1–3):3–13. [PubMed: 15464016]
- Gudelsky GA, Nash JF. Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: Implications for serotonin-dopamine interactions. *J. Neurochem.* 1996; 66:243–249. [PubMed: 8522960]
- Gurtman CG, Morley KC, Li KM, Hunt GE, McGregor IS. Increased anxiety in rats after 3,4-methylenedioxymethamphetamine: Association with serotonin depletion. *Eur. J. Pharmacol.* 2002; 446(1–3):89–96. [PubMed: 12098589]
- Hajos M, Sharp T. A 5-hydroxytryptamine lesion markedly reduces the incidence of burst-firing dorsal raphe neurones in the rat. *Neurosci. Lett.* 1996; 204(3):161–164. [PubMed: 8938255]
- Halladay AK, Wagner GC, Sekowski A, Rothman RB, Baumann MH, Fisher H. Alterations in alcohol consumption, withdrawal seizures, and monoamine transmission in rats treated with phentermine and 5-hydroxy-L-tryptophan. *Synapse.* 2006; 59(5):277–289. [PubMed: 16416445]
- Hall FS, Devries AC, Fong GW, Huang S, Pert A. Effects of 5,7-dihydroxytryptamine depletion of tissue serotonin levels on extracellular serotonin in the striatum assessed with *in vivo* microdialysis: Relationship to behavior. *Synapse.* 1999; 33(1):16–25. [PubMed: 10380847]
- Harris DS, Baggott M, Mendelson JH, Mendelson JE, Jones RT. Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. *Psychopharmacology (Berl.).* 2002; 162(4):396–405. [PubMed: 12172693]
- Hendrikx M, Van Dorpe J, Flameng W, Daenen W. Aortic and mitral valve disease induced by ergotamine therapy for migraine: A case report and review of the literature. *J. Heart Valve Dis.* 1996; 5:235–237. [PubMed: 8665020]
- Johanson CE, Kilbey M, Gatchalian K, Tancer M. Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans trained to discriminate among d-amphetamine, meta-chlorophenylpiperazine and placebo. *Drug Alcohol Depend.* 2005; 81:27–36. [PubMed: 15975736]

- Johnson MP, Hoffman AJ, Nichols DE. Effects of the enantiomers of MDA,MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices. *Eur. J. Pharmacol.* 1986; 132(2–3):269–276. [PubMed: 2880735]
- Kalia M, O'Callaghan JP, Miller DB, Kramer M. Comparative study of fluoxetine, sibutramine, sertraline and dexfenfluramine on the morphology of serotonergic nerve terminals using serotonin immunohistochemistry. *Brain Res.* 2000; 858:92–105. [PubMed: 10700602]
- Kankaanpää A, Meririnne E, Lillsunde P, Seppälä T. The acute effects of amphetamine derivatives on extracellular serotonin and dopamine levels in rat nucleus accumbens. *Pharmacol. Biochem. Behav.* 1998; 59(4):1003–1009. [PubMed: 9586861]
- Kirby LG, Kreiss DS, Singh A, Lucki I. Effect of destruction of serotonin neurons on basal and fenfluramine-induced serotonin release in striatum. *Synapse.* 1995; 20(2):99–105. [PubMed: 7570349]
- Kish SJ. How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy? *Pharmacol. Biochem. Behav.* 2002; 71(4):845–855. [PubMed: 11888575]
- Kleiber M. Body size and metabolism. *Hilgardia.* 1932; 6:315–353.
- Landry MJ. MDMA: A review of epidemiologic data. *J. Psychoactive Drugs.* 2002; 34(2):163–169. [PubMed: 12691206]
- Lavelle A, Honner V, Docherty JR. Investigation of the prejunctional alpha2-adrenoceptor mediated actions of MDMA in rat atrium and vas deferens. *Br. J. Pharmacol.* 1999; 128(5):975–980. [PubMed: 10556934]
- Levy AD, Baumann MH, Van de Kar LD. Monoaminergic regulation of neuroendocrine function and its modification by cocaine. *Front. Neuroendocrinol.* 1994; 15:85–156. [PubMed: 7813744]
- Liechti ME, Vollenweider FX. Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. *Hum. Psychopharmacol.* 2001; 16(8):589–598. [PubMed: 12404538]
- Liechti ME, Baumann C, Gamma A, Vollenweider FX. Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”) are attenuated by the serotonin uptake inhibitor citalopram. *Neuropsychopharmacology.* 2000; 22(5):513–521. [PubMed: 10731626]
- Lin JH. Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. *Drug Metab. Dispos.* 1998; 26:1202–1212. [PubMed: 9860929]
- Lopez-Illasaca M. Signaling from G-protein-coupled receptors to mitogen-activated protein (MAP)-kinase cascades. *Biochem. Pharmacol.* 1998; 56:269–277. [PubMed: 9744561]
- Lyles J, Cadet JL. Methylenedioxymethamphetamine (MDMA, Ecstasy) neurotoxicity: Cellular and molecular mechanisms. *Brain Res. Brain Res. Rev.* 2003; 42(2):155–168. [PubMed: 12738056]
- Lyon RA, Glennon RA, Titeler M. 3,4-Methylenedioxymethamphetamine (MDMA): Stereoselective interactions at brain 5-HT1 and 5-HT2 receptors. *Psychopharmacology (Berl.).* 1986; 88(4):525–526. [PubMed: 2871581]
- Mahmood I. Allometric issues in drug development. *J. Pharm. Sci.* 1999; 88:1101–1106. [PubMed: 10564055]
- Malberg JE, Seiden LS. Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. *J. Neurosci.* 1998; 18:5086–5094. [PubMed: 9634574]
- Malpass A, White JM, Irvine RJ, Somogyi AA, Bochner F. Acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA) in Sprague-Dawley and Dark Agouti rats. *Pharmacol. Biochem. Behav.* 1999; 64(1):29–34. [PubMed: 10494994]
- Marston HM, Reid ME, Lawrence JA, Olverman HJ, Butcher SP. Behavioural analysis of the acute and chronic effects of MDMA treatment in the rat. *Psychopharmacology (Berl.).* 1999; 144(1):67–76. [PubMed: 10379626]
- Mas M, Farre M, de la Torre R, Roset PN, Ortuno J, Segura J, Cami J. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4- methylenedioxymethamphetamine in humans. *J. Pharmacol. Exp. Ther.* 1999; 290:136–145. [PubMed: 10381769]
- Matuszewicz L, Filon ME, Finn DA, Yamamoto BK. Altered forebrain neurotransmitter responses to immobilization stress following 3,4-methylenedioxymethamphetamine. *Neuroscience.* 2002; 110(1):41–48. [PubMed: 11882371]

- Maurer HH, Bickeboeller-Friedrich J, Kraemer T, Peters FT. Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('Ecstasy'). *Toxicol. Lett.* 2000; 112–113:133–142.
- McCann UD, Szabo Z, Vranesic M, Palermo M, Mathews WB, Ravert HT, Dannals RF, Ricaurte GA. Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/–)3,4-methylenedioxymethamphetamine ("ecstasy") users: Relationship to cognitive performance. *Psychopharmacology (Berl.)*. 2008; 200(3):439–450. [PubMed: 18661256]
- McGregor IS, Clemens KJ, Van der Plasse G, Li KM, Hunt GE, Chen F, Lawrence AJ. Increased anxiety 3 months after brief exposure to MDMA ("Ecstasy") in rats: Association with altered 5-HT transporter and receptor density. *Neuropsychopharmacology*. 2003; 28(8):1472–1484. [PubMed: 12700695]
- McNamara MG, Kelly JP, Leonard BE. Some behavioural and neurochemical aspects of subacute (+/–)3,4-methylenedioxymethamphetamine administration in rats. *Pharmacol. Biochem. Behav.* 1995; 52(3):479–484. [PubMed: 8545462]
- Mechan AO, Esteban B, O'Shea E, Elliott JM, Colado MI, Green AR. The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats. *Br. J. Pharmacol.* 2002; 135(1):170–180. [PubMed: 11786492]
- Mechan A, Yuan J, Hatzidimitriou G, Irvine RJ, McCann UD, Ricaurte GA. Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: Relationship to lasting effects on brain serotonin neurons. *Neuropsychopharmacology*. 2006; 31(2):339–350. [PubMed: 15999148]
- Molliver ME, Berger UV, Mamounas LA, Molliver DC, O'Hearn E, Wilson MA. Neurotoxicity of MDMA and related compounds: Anatomic studies. *Ann. NY Acad. Sci.* 1990; 600:649–661. (discuss). [PubMed: 1979216]
- Monks TJ, Jones DC, Bai F, Lau SS. The role of metabolism in 3,4-(+)-methylenedioxyamphetamine and 3,4-(+)-methylenedioxymethamphetamine (ecstasy) toxicity. *Ther. Drug Monit.* 2004; 26(2):132–136. [PubMed: 15228153]
- Morgan MJ. Ecstasy (MDMA): A review of its possible persistent psychological effects. *Psychopharmacology (Berl.)*. 2000; 152(3):230–248. [PubMed: 11105933]
- Morley KC, Gallate JE, Hunt GE, Mallet PE, McGregor IS. Increased anxiety and impaired memory in rats 3 months after administration of 3,4-methylenedioxymethamphetamine ("ecstasy"). *Eur. J. Pharmacol.* 2001; 433(1):91–99. [PubMed: 11755138]
- Moser VC. The functional observational battery in adult and developing rats. *Neurotoxicology*. 2000; 21(6):989–996. [PubMed: 11233768]
- Mueller M, Peters FT, Maurer HH, McCann UD, Ricaurte GA. Nonlinear pharmacokinetics of (+/–)3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") and its major metabolites in squirrel monkeys at plasma concentrations of MDMA that develop after typical psychoactive doses. *J. Pharmacol. Exp. Ther.* 2008; 327(1):38–44. [PubMed: 18591215]
- Nash JF Jr, Meltzer HY, Gudelsky GA. Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4-methylenedioxymethamphetamine. *J. Pharmacol. Exp. Ther.* 1988; 245(3):873–879. [PubMed: 2898523]
- Nichols DE, Lloyd DH, Hoffman AJ, Nichols MB, Yim GK. Effects of certain hallucinogenic amphetamine analogues on the release of [3H]serotonin from rat brain synaptosomes. *J. Med. Chem.* 1982; 25(5):530–535. [PubMed: 7086839]
- Noujaim SF, Lucca E, Munoz V, Persaud D, Berenfeld O, Meijler FL, Jalife J. From mouse to whale: A universal scaling relation for the PR Interval of the electrocardiogram of mammals. *Circulation*. 2004; 110(18):2802–2808. [PubMed: 15505092]
- Oberlender R, Nichols DE. Drug discrimination studies with MDMA and amphetamine. *Psychopharmacology (Berl.)*. 1988; 95(1):71–76. [PubMed: 2898791]
- O'Cain PA, Hletko SB, Ogden BA, Varner KJ. Cardiovascular and sympathetic responses and reflex changes elicited by MDMA. *Physiol. Behav.* 2000; 70(1–2):141–148. [PubMed: 10978489]
- O'Hearn E, Battaglia G, De Souza EB, Kuhar MJ, Molliver ME. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: Immunocytochemical evidence for neurotoxicity. *J. Neurosci.* 1988; 8(8):2788–2803. [PubMed: 2457659]

- O'Shea E, Granados R, Esteban B, Colado MI, Green AR. The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy'). *Neuropharmacology*. 1998; 37(7):919–926. [PubMed: 9776387]
- Parrott AC. Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. *Pharmacol. Biochem. Behav.* 2002; 71(4):837–844. [PubMed: 11888574]
- Parrott AC. Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity. *Psychopharmacology (Berl.)*. 2004; 173(3–4):234–241. [PubMed: 15007594]
- Parrott AC. Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy. *J. Psychopharmacol.(Oxford)*. 2005; 19(1):71–83. [PubMed: 15671132]
- Partilla JS, Dersch CM, Yu H, Rice KC, Rothman RB. Neurochemical neutralization of amphetamine-type stimulants in rat brain by the indatraline analog (–)-HY038. *Brain Res. Bull.* 2000; 53(6): 821–826. [PubMed: 11179849]
- Pifl C, Wolf A, Rebernik P, Reither H, Berger ML. Zinc regulates the dopamine transporter in a membrane potential and chloride dependent manner. *Neuropharmacology*. 2009; 56(2):531–540. [PubMed: 19000913]
- Poland RE. Diminished corticotropin and enhanced prolactin responses to 8-hydroxy-2(di-n-propylamino) tetralin in methylenedioxymethamphetamine pretreated rats. *Neuropharmacology*. 1990; 29(11):1099–1101. [PubMed: 1982341]
- Poland RE, Lutchmansingh P, McCracken JT, Zhao JP, Brammer GL, Grob CS, Boone KB, Pechnick RN. Abnormal ACTH and prolactin responses to fenfluramine in rats exposed to single and multiple doses of MDMA. *Psychopharmacology (Berl.)*. 1997; 131(4):411–419. [PubMed: 9226745]
- Porter RH, Benwell KR, Lamb H, Malcolm CS, Allen NH, Revell DF, Adams DR, Sheardown MJ. Functional characterization of agonists at recombinant human 5-HT_{2A}, 5-HT_{2B} and 5-HT_{2C} receptors in CHO-K1 cells. *Br. J. Pharmacol.* 1999; 128:13–20. [PubMed: 10498829]
- Ratzenboeck E, Saria A, Kriechbaum N, Zernig G. Reinforcing effects of MDMA ("ecstasy") in drug-naive and cocaine-trained rats. *Pharmacology*. 2001; 62(3):138–144. [PubMed: 11287814]
- Reneman L. Designer drugs: How dangerous are they? *J. Neural Transm. Suppl.* 2003; 66:61–83. [PubMed: 14582803]
- Ricaurte GA, Markowska AL, Wenk GL, Hatzidimitriou G, Wlos J, Olton DS. 3,4-Methylenedioxymethamphetamine, serotonin and memory. *J. Pharmacol. Exp. Ther.* 1993; 266:1097–1105. [PubMed: 8102642]
- Ricaurte GA, Yuan J, McCann UD. (+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: Studies in animals. *Neuropsychobiology*. 2000; 42(1):5–10. [PubMed: 10867550]
- Robinson TE, Castaneda E, Whishaw IQ. Effects of cortical serotonin depletion induced by 3,4-methylenedioxymethamphetamine (MDMA) on behavior, before and after additional cholinergic blockade. *Neuropsychopharmacology*. 1993; 8(1):77–85. [PubMed: 8093836]
- Romero L, Jernej B, Bel N, Cicin-Sain L, Cortes R, Artigas F. Basal and stimulated extracellular serotonin concentration in the brain of rats with altered serotonin uptake. *Synapse*. 1998; 28(4): 313–321. [PubMed: 9517840]
- Roth BL. Drugs and valvular heart disease. *N. Engl. J. Med.* 2007; 356(1):6–9. [PubMed: 17202450]
- Rothman RB, Baumann MH. Therapeutic potential of monoamine transporter substrates. *Curr. Top. Med. Chem.* 2006; 6(17):1845–1859. [PubMed: 17017961]
- Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufisein S, Roth BL. Evidence for possible involvement of 5-HT_{2B} receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. *Circulation*. 2000; 102:2836–2841. [PubMed: 11104741]
- Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. *Synapse*. 2001; 39:32–41. [PubMed: 11071707]

- Rudnick G, Clark J. From synapse to vesicle: The reuptake and storage of biogenic amine neurotransmitters. [Review]. *Biochim. Biophys. Acta*. 1993; 1144:249–263. [PubMed: 8104483]
- Scanzello CR, Hatzidimitriou G, Martello AL, Katz JL, Ricaurte GA. Serotonergic recovery after (+/-)-3,4-(methylenedioxy) methamphetamine injury: Observations in rats. *J. Pharmacol. Exp. Ther.* 1993; 264:1484–1491. [PubMed: 7680719]
- Schechter MD. Serotonergic-dopaminergic mediation of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”). *Pharmacol. Biochem. Behav.* 1988; 31(4):817–824. [PubMed: 2908067]
- Schenk S, Gittings D, Johnstone M, Daniela E. Development, maintenance and temporal pattern of self-administration maintained by ecstasy (MDMA) in rats. *Psychopharmacology (Berl)*. 2003; 169(1):21–27. [PubMed: 12774185]
- Schifano F. A bitter pill. Overview of ecstasy (MDMA, MDA) related fatalities. *Psychopharmacology (Berl.)*. 2004; 173(3–4):242–248. [PubMed: 14673568]
- Schmidt CJ. Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. *J. Pharmacol. Exp. Ther.* 1987; 240(1):1–7. [PubMed: 2433425]
- Schmidt CJ, Levin JA, Lovenberg W. In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. *Biochem. Pharmacol.* 1987; 36(5):747–755. [PubMed: 2881549]
- Seiden LS, Woolverton WL, Lorens SA, Williams JE, Corwin RL, Hata N, Olinski M. Behavioral consequences of partial monoamine depletion in the CNS after methamphetamine-like drugs: The conflict between pharmacology and toxicology. *NIDA Res. Monogr.* 1993; 136:34–46. (discussion 46–52). [PubMed: 8289913]
- Selken J, Nichols DE. Alpha1-adrenergic receptors mediate the locomotor response to systemic administration of (+/-)-3,4-methylenedioxymethamphetamine (MDMA) in rats. *Pharmacol. Biochem. Behav.* 2007; 86(4):622–630. [PubMed: 17363047]
- Series HG, Cowen PJ, Sharp T. *p*-Chloroamphetamine (PCA), 3,4-methylenedioxymethamphetamine (MDMA) and d-fenfluramine pretreatment attenuates d-fenfluramine-evoked release of 5-HT *in vivo*. *Psychopharmacology (Berl.)*. 1994; 116:508–514. [PubMed: 7535469]
- Series HG, le Masurier M, Gartside SE, Franklin M, Sharp T. Behavioural and neuroendocrine responses to d-fenfluramine in rats treated with neurotoxic amphetamines. *J. Psychopharmacol.* 1995; 9:214–222.
- Setola V, Roth BL. Screening the receptorome reveals molecular targets responsible for drug-induced side effects: Focus on ‘fen-phen’. *Expert Opin. Drug Metab. Toxicol.* 2005; 1(3):377–387. [PubMed: 16863450]
- Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, Roth BL. 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells *in vitro*. *Mol. Pharmacol.* 2003; 63(6):1223–1229. [PubMed: 12761331]
- Seuwen K, Magnaldo I, Pouyssegur J. Serotonin stimulates DNA synthesis in fibroblasts acting through 5-HT1B receptors coupled to a Gi-protein. *Nature*. 1988; 335:254–256. [PubMed: 3045568]
- Shankaran M, Gudelsky GA. A neurotoxic regimen of MDMA suppresses behavioral, thermal and neurochemical responses to subsequent MDMA administration. *Psychopharmacology (Berl)*. 1999; 147(1):66–72. [PubMed: 10591870]
- Slikker W Jr, Holson RR, Ali SF, Kolta MG, Paule MG, Scallet AC, McMillan DE, Bailey JR, Hong JS, Scalzo FM. Behavioral and neurochemical effects of orally administered MDMA in the rodent and nonhuman primate. *Neurotoxicology*. 1989; 10(3):529–542. [PubMed: 2576304]
- Spanos LJ, Yamamoto BK. Acute and subchronic effects of methylenedioxymethamphetamine [(+/-)MDMA] on locomotion and serotonin syndrome behavior in the rat. *Pharmacol. Biochem. Behav.* 1989; 32:835–840. [Published erratum appears in *Pharmacol. Biochem. Behav.* 1989 Nov;34 (3):679]. [PubMed: 2572003]
- Sprague JE, Everman SL, Nichols DE. An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. *Neurotoxicology*. 1998; 19:427–441. [PubMed: 9621349]

- Sprouse JS, Bradberry CW, Roth RH, Aghajanian GK. MDMA (3,4-methylenedioxymethamphetamine) inhibits the firing of dorsal raphe neurons in brain slices via release of serotonin. *Eur. J. Pharmacol.* 1989; 167(3):375–383. [PubMed: 2572435]
- Starr MA, Page ME, Waterhouse BD. MDMA (3,4-methylenedioxymethamphetamine)-mediated distortion of somatosensory signal transmission and neurotransmitter efflux in the ventral posterior medial thalamus. *J. Pharmacol. Exp. Ther.* 2008; 327(1):20–31. [PubMed: 18606872]
- Steinbusch HW. Distribution of serotonin-immunoreactivity in the central nervous system of the rat-cell bodies and terminals. *Neuroscience.* 1981; 6:557–618. [PubMed: 7017455]
- Stone DM, Merchant KM, Hanson GR, Gibb JW. Immediate and long-term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat. *Neuropharmacology.* 1987; 26(12):1677–1683. [PubMed: 2893986]
- Tancer M, Johanson CE. Reinforcing, subjective, and physiological effects of MDMA in humans: A comparison with d-amphetamine and mCPP. *Drug Alcohol Depend.* 2003; 72(1):33–44. [PubMed: 14563541]
- Thomasius R, Zaplova P, Petersen K, Buchert R, Andresen B, Wartberg L, Nebeling B, Schmoldt A. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: The longitudinal perspective. *J. Psychopharmacol. (Oxford, England).* 2006; 20(2):211–225.
- Van de Kar LD. Neuroendocrine pharmacology of serotonergic (5-HT) neurons. *Annu. Rev. Pharmacol. Toxicol.* 1991; 31:289–320. [PubMed: 2064377]
- Verheyden SL, Henry JA, Curran HV. Acute, sub-acute and long-term subjective consequences of ‘ecstasy’ (MDMA) consumption in 430 regular users. *Hum. Psychopharmacol.* 2003; 18(7):507–517. [PubMed: 14533132]
- Vollenweider FX, Gamma A, Liechti M, Huber T. Psychological and cardiovascular effects and short-term sequelae of MDMA (“ecstasy”) in MDMA-naïve healthy volunteers. *Neuropsychopharmacology.* 1998; 19:241–251. [PubMed: 9718588]
- Wakonigg G, Sturm K, Saria A, Zernig G. Methylenedioxymethamphetamine (MDMA, ‘ecstasy’) serves as a robust positive reinforcer in a rat runway procedure. *Pharmacology.* 2003; 69(4):180–182. [PubMed: 14624057]
- Wang X, Baumann MH, Dersch CM, Rothman RB. Restoration of 3,4-methylenedioxymethamphetamine-induced 5-HT depletion by the administration of 1-5-hydroxytryptophan. *Neuroscience.* 2007; 148(1):212–220. [PubMed: 17629409]
- West GB, Woodruff WH, Brown JH. Allometric scaling of metabolic rate from molecules and mitochondria to cells and mammals. *Proc. Natl. Acad. Sci. USA.* 2002; 99 Suppl. 1:2473–2478. [PubMed: 11875197]
- White CR, Seymour RS. Allometric scaling of mammalian metabolism. *J. Exp. Biol.* 2005; 208(Pt 9): 1611–1619. [PubMed: 15855392]
- Winneke G, Lilienthal H. Extrapolation from animals to humans: Scientific and regulatory aspects. *Toxicol. Lett.* 1992; 64–65 (Spec No: 239–246).
- Wu D, Otton SV, Inaba T, Kalow W, Sellers EM. Interactions of amphetamine analogs with human liver CYP2D6. *Biochem. Pharmacol.* 1997; 53(11):1605–1612. [PubMed: 9264312]
- Yacoubian GS Jr. Tracking ecstasy trends in the United States with data from three national drug surveillance systems. *J. Drug Educ.* 2003; 33(3):245–258. [PubMed: 15022859]
- Yamamoto BK, Nash JF, Gudelsky GA. Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra. *J. Pharmacol. Exp. Ther.* 1995; 273(3):1063–1070. [PubMed: 7791076]
- Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Stricker EM. Compensations after lesions of central dopaminergic neurons: Some clinical and basic implications. *Trends Neurosci.* 1990; 13(7):290–296. [PubMed: 1695406]

Amphetamine

3,4-methylenedioxyamphetamine
(MDA)

Methamphetamine

3,4-methylenedioxymethamphetamine
(MDMA)

FIG. 1.
Chemical structures of MDMA and related amphetamines.

FIG. 2.

Effects of i.v. MDMA on concentrations of 5-HT (top panel) and DA (bottom panel) in dialysate samples obtained from rat n. accumbens. Conscious rats undergoing *in vivo* microdialysis received i.v. injections of 1 mg/kg MDMA at time zero followed by 3 mg/kg 60 min later. Dialysate samples obtained at 20 min intervals were assayed for 5-HT and DA by HPLC-ECD. Data are mean $\pm$ S.E.M., expressed as pg/5 μ l sample for $N = 7$ rats/group. * $P < 0.05$ versus preinjection baseline. (Modified from Baumann *et al.*, 2005).

FIG. 3.

Correlations between dialysate 5-HT in the n. accumbens versus ambulation (top panel) and stereotypy (bottom panel) produced by MDMA. Conscious rats undergoing *in vivo* microdialysis received i.v. injections of 1 mg/kg MDMA at time zero followed by 3 mg/kg 60 min later. Data points represent raw values obtained at 20 min intervals, from +20 min (first sample after 1 mg/kg) through +120 min (last sample after 3 mg/kg) for $N=6$ rats. Pearson correlation coefficients (r) are shown with corresponding P values. (Modified from Baumann *et al.*, 2008b).

FIG. 4.

Correlations between dialysate DA in the n. accumbens versus ambulation (top panel) and stereotypy (bottom panel) produced by MDMA. Conscious rats undergoing *in vivo* microdialysis received i.v. injections of 1 mg/kg MDMA at time zero followed by 3 mg/kg 60 min later. Data points represent raw values obtained at 20 min intervals, from +20 min (first sample after 1 mg/kg) through +120 min (last sample after 3 mg/kg) for $N = 6$ rats. Pearson correlation coefficients (r) are shown with corresponding P values. (Modified from Baumann *et al.*, 2008b).

FIG. 5. Metabolism of MDMA in humans. The main cytochrome P450 (CYP) isoforms responsible for particular biotransformation reactions are indicated in *italics*. Thick arrows highlight major pathways, whereas thin arrows represent minor pathways.

FIG. 6.

Effects of MDMA binge administration on body temperature in rats. Male rats received three i.p. injections of saline, 1.5 mg/kg (low dose) or 7.5 mg/kg MDMA (high dose); injections were given at time 0, 2, and 4 h. Core body temperature was monitored hourly via insertion of a rectal temperature probe. Data are degrees Celsius expressed as mean $\pm$ S.E.M. for $N = 6$ rats/group. * $P < 0.05$ compared to saline control at a given time point.

FIG. 7.

Effects of MDMA binge administration on tissue levels of 5-HT (top panel) and DA (bottom panel) in microdissected rat brain regions. Male rats received three i.p. injections of saline, 1.5 mg/kg (low dose) or 7.5 mg/kg MDMA (high dose). Rats were decapitated 2 weeks later, and tissue was dissected from n. accumbens (NAC), striatum (STR) and mediobasal hypothalamus (HYP). Postmortem concentrations of 5-HT and DA were quantified by HPLC-ECD. Data are pg/mg wet weight expressed as mean $\pm$ S.E.M. for $N = 6$ rats/group. * $P < 0.05$ compared to saline control for a specified brain region.

FIG. 8.

Correlations between acute body temperature versus postmortem tissue levels of 5-HT (top panel) and DA (bottom panel) in rat n. accumbens measured 2 weeks after MDMA administration. Body temperatures represent average values obtained from 1 to 6 h after MDMA or saline injections, as shown in Fig. 6. Postmortem tissue levels of 5-HT and DA were measured 2 weeks later by HPLC-ECD, as shown in Fig. 7. Data points represent average temperature versus tissue amine concentration from individual rats ($N = 18$ rats), and Pearson correlation coefficients (r) are given. (Modified from Baumann *et al.*, 2008a).

FIG. 9.

Effects of i.v. MDMA on plasma concentrations of prolactin (top panel) and corticosterone (bottom panel) in rats pretreated with saline or MDMA binges. Male rats received three i.p. injections of saline, 1.5 mg/kg (low dose) or 7.5 mg/kg MDMA (high dose). Two weeks later, rats were given i.v. challenge injections of 1 mg/kg MDMA at time 0 h, followed by 3 mg/kg at 60 min. Blood samples were withdrawn immediately before and at 15, 30, and 60 min after each drug injection. Plasma hormones were assayed by double-antibody RIA methods. Data are ng/ml expressed as mean $\pm$ S.E. M. for $N = 8$ rats/group. * $P < 0.05$ compared to saline-pretreated control at a given time point. (Modified from Baumann *et al.*, 2008a).

FIG. 10.

Effects of i.v. MDMA on 5-HT behavioral syndrome in rats pretreated with saline or MDMA binges. Male rats received three i.p. injections of saline, 1.5 mg/kg (low dose) or 7.5 mg/kg MDMA (high dose). Two weeks later, rats were given i.v. challenge injections of 1 mg/kg MDMA at time 0 h, followed by 3 mg/kg at 60 min. The occurrence of flat-body posture and forepaw treading were scored after each dose of acute i.v. MDMA. Data are summed syndrome scores expressed as mean $\pm$ S.E.M. for $N = 8$ rats/group. * $P < 0.05$ compared to saline-pretreated control at the corresponding challenge dose of MDMA. (Modified from Baumann *et al.*, 2008a).

FIG. 11.

Effects of i.v. MDMA on dialysate 5-HT (top panel) and DA (bottom panel) in n. accumbens of rats pretreated with saline or MDMA binges. Male rats received three i.p. injections of saline, 1.5 mg/kg (low dose) or 7.5 mg/kg MDMA (high dose). Two weeks later, rats undergoing *in vivo* microdialysis were given i.v. challenge injections of 1 mg/kg MDMA at time 0 h, followed by 3 mg/kg at 60 min. Dialysate samples collected at 20 min intervals were assayed for 5-HT and DA by microbore HPLC-ECD. Data are pg/5 µl expressed as mean $\pm$ S.E.M. for $N=8$ rats/group. * $P < 0.05$ compared to saline-pretreated control at a given time point. (Modified from Baumann *et al.*, 2008a).

FIG. 12. Effects of MDMA on brain 5-HT as measured by immunoautoradiography. Male rats received three i.p. injections of saline or 7.5 mg/kg MDMA. Two weeks later, rats were treated with i.p. injections of either saline or 5-HTP/benserazide (5-HTP-B, 50 mg/kg of each drug), and were decapitated 2 h thereafter. 5-HT was measured by immunoautoradiography in postmortem brain sections. Values are mean ± S.D. for $N=6$ rats/group, and representative autoradiograms are shown. * $P < 0.01$ compared to control; † $P < 0.01$ compared to corresponding MDMA-treated group. Taken from Wang *et al.*, 2007.

TABLE I

Profile of MDMA and Related Compounds as Monoamine Transporter Substrates in Rat Brain Synaptosomes

Drug	5-HT release EC ₅₀ (nM ± S.D.)	NE release EC ₅₀ (nM ± S.D.)	DA release EC ₅₀ (nM ± S.D.)
(+)-Methamphetamine	736 ± 45	12 ± 0.7	24 ± 2
(-)-Methamphetamine	4640 ± 240	29 ± 3	416 ± 20
(±)-MDMA	74.3 ± 5.6	136 ± 17	278 ± 12
(+)-MDMA	70.8 ± 5.2	110 ± 16	142 ± 6
(-)-MDMA	337 ± 34	564 ± 60	3682 ± 178
(+)-Amphetamine	1765 ± 94	7.1 ± 1.0	25 ± 4
(±)-MDA	159 ± 12	108 ± 12	290 ± 10
(+)-MDA	99.6 ± 7.4	98.5 ± 6.1	50.0 ± 8.0
(-)-MDA	313 ± 21	287 ± 23	900 ± 49

Data are taken from Partilla *et al.* (2000), Rothman *et al.* (2001), and Setola *et al.* (2003). Details concerning *in vitro* methods can be found in these papers. Substrate activity at SERT, NET, and DAT is reflected as release efficacy for the corresponding transmitter.

TABLE II

Long-Term Effects of ($\pm$)-MDMA on 5-HT Neuronal Markers in Rats

5-HT deficit	Dose	Survival interval	References
Depletions of 5-HT in cortex, as measured by HPLC-ECD	10 mg/kg, s.c., single dose	1 week	Schmidt (1987)
Depletions of 5-HT in forebrain regions as measured by HPLC-ECD	10–40 mg/kg, s.c., twice daily, 4 days	2 weeks	Commins <i>et al.</i> (1987)
Reductions in tryptophan hydroxylase activity in forebrain regions	10 mg/kg, s.c., single dose	2 weeks	Stone <i>et al.</i> (1987)
Loss of [3 H]-paroxetine-labeled SERT binding sites in forebrain regions	20 mg/kg, s.c., twice daily, 4 days	2 weeks	Battaglia <i>et al.</i> (1987)
Decreased immunoreactive 5-HT in fine axons and terminals in forebrain regions	20 mg/kg, s.c., twice daily, 4 days	2 weeks	O'Hearn <i>et al.</i> (1988)

TABLE III

Comparative Neurobiological Effects of (±)-MDMA Administration in Rats and Humans

CNS effect	Dose in rats	Dose in humans
<i>In vivo</i> release of 5-HT and DA	2.5 mg/kg, i.p. (Gudelsky and Nash, 1996); 1 mg/kg, s.c. (Kankaanpää <i>et al.</i> , 1998)	1.5 mg/kg p.o. (Liechti <i>et al.</i> , 2000; Liechti and Vollenweider, 2001) ^a
Secretion of prolactin and glucocorticoids	1–3 mg/kg, i.p. (Nash <i>et al.</i> , 1988)	1.67 mg/kg, p.o. (Mas <i>et al.</i> , 1999); 1.5 mg/kg, p.o. (Harris <i>et al.</i> , 2002)
Drug discrimination	1.5 mg/kg, i.p. (Oberlender and Nichols, 1988; Schechter, 1988)	1.5 mg/kg, p.o. (Johanson <i>et al.</i> , 2005)
Drug reinforcement	1 mg/kg, i.v. (Wakonigg <i>et al.</i> , 2003)	1–2 mg/kg, p.o. (Tancer and Johanson, 2003) ^b

^a Subjective effects were attenuated by 5-HT uptake blockers, suggesting the involvement of transporter-mediated 5-HT release.

^b Reinforcing effects were determined based on a multiple choice procedure.

TABLE IV

Effects of ($\pm$)-MDMA Administration on Functional Indices of 5-HT Transmission in Rats

CNS effect	Dosing regimen	Survival interval	References
No change in 5-HT cell firing	20 mg/kg, s.c., twice daily, 4 days	2 weeks	Gartside <i>et al.</i> (1996)
Changes in corticosterone and prolactin secretion	20 mg/kg, s.c., single dose; 20 mg/kg, s.c. twice daily, 4 days	2 weeks 4, 8, and 12 months	Poland <i>et al.</i> (1997)
Reductions in evoked 5-HT release <i>in vivo</i>	20 mg/kg, s.c., twice daily, 4 days; 10 mg/kg, i.p., twice daily, 4 days	2 weeks, 1 week	Series <i>et al.</i> (1994), Shankaran and Gudelsky (1999)
Increased anxiety-like behaviors	5 mg/kg, s.c., 1 or 4 injections, 2 days; 7.5 mg/kg, s.c., twice daily, 3 days	3 months; 2 weeks	McGregor <i>et al.</i> (2003), Morley <i>et al.</i> (2001), ^a Fone <i>et al.</i> (2002) ^a

^aThese investigators noted marked increases in anxiogenic behaviors in the absence of significant MDMA-induced 5-HT depletion in brain.

TABLE V

Potency (pEC₅₀) and Efficacy of MDMA and MDA for Activation of 5-HT_{2B}-Mediated PI Hydrolysis

Test drug	pEC ₅₀ for 5-HT _{2B} -mediated PI hydrolysis (nM)	Efficacy for 5-HT _{2B} -mediated PI hydrolysis (relative to 5-HT)
5-HT	1.0	1.0
(±)-MDMA	2000	0.32
(+)-MDMA	900	0.27
(-)-MDMA	6000	0.38
(±)-MDA	190	0.80
(+)-MDA	150	0.76
(-)-MDA	100	0.81
Fenfluramine	400	0.13
Norfenfluramine	60	0.96
Dihydroergotamine	30	0.73
Pergolide	53	1.12
Methysergide	150	0.18
Methylegonivine	0.8	0.40

Data are mean values for $\mathcal{N} = 3$ experiments. Data taken from Setola *et al.* (2003).